JP6863548B2 - Cosmetic base for improving skin condition and its screening method - Google Patents
Cosmetic base for improving skin condition and its screening method Download PDFInfo
- Publication number
- JP6863548B2 JP6863548B2 JP2016094588A JP2016094588A JP6863548B2 JP 6863548 B2 JP6863548 B2 JP 6863548B2 JP 2016094588 A JP2016094588 A JP 2016094588A JP 2016094588 A JP2016094588 A JP 2016094588A JP 6863548 B2 JP6863548 B2 JP 6863548B2
- Authority
- JP
- Japan
- Prior art keywords
- stratum corneum
- skin
- oil
- acid
- poe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002537 cosmetic Substances 0.000 title claims description 45
- 238000000034 method Methods 0.000 title claims description 20
- 238000012216 screening Methods 0.000 title claims description 20
- 210000000434 stratum corneum Anatomy 0.000 claims description 142
- 210000003491 skin Anatomy 0.000 claims description 136
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 230000015572 biosynthetic process Effects 0.000 claims description 33
- 230000006872 improvement Effects 0.000 claims description 24
- 230000014759 maintenance of location Effects 0.000 claims description 8
- 230000035699 permeability Effects 0.000 claims description 8
- -1 Hexyldecyl Chemical group 0.000 description 58
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 50
- 239000003921 oil Substances 0.000 description 42
- 235000019198 oils Nutrition 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 35
- 235000014113 dietary fatty acids Nutrition 0.000 description 26
- 239000000194 fatty acid Substances 0.000 description 26
- 229930195729 fatty acid Natural products 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 18
- 102000005708 Desmoglein 1 Human genes 0.000 description 15
- 108010045579 Desmoglein 1 Proteins 0.000 description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000004359 castor oil Substances 0.000 description 12
- 235000019438 castor oil Nutrition 0.000 description 12
- 239000003995 emulsifying agent Substances 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 12
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 12
- 235000011187 glycerol Nutrition 0.000 description 11
- 150000005846 sugar alcohols Polymers 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 239000000049 pigment Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 238000012744 immunostaining Methods 0.000 description 8
- 239000010445 mica Substances 0.000 description 8
- 229910052618 mica group Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 7
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 239000002734 clay mineral Substances 0.000 description 5
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 5
- 238000002834 transmittance Methods 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 229940105990 diglycerin Drugs 0.000 description 3
- 229940008099 dimethicone Drugs 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- MSPJNHHBNOLHOC-UHFFFAOYSA-N 3,3-dimethylcyclopropane-1,2-dicarboxylic acid Chemical compound CC1(C)C(C(O)=O)C1C(O)=O MSPJNHHBNOLHOC-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 102000011799 Desmoglein Human genes 0.000 description 2
- 108050002238 Desmoglein Proteins 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- QZXSMBBFBXPQHI-UHFFFAOYSA-N N-(dodecanoyl)ethanolamine Chemical compound CCCCCCCCCCCC(=O)NCCO QZXSMBBFBXPQHI-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 229940073609 bismuth oxychloride Drugs 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000010495 camellia oil Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- XLLIQLLCWZCATF-UHFFFAOYSA-N ethylene glycol monomethyl ether acetate Natural products COCCOC(C)=O XLLIQLLCWZCATF-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 2
- FIPPFBHCBUDBRR-UHFFFAOYSA-N henicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCO FIPPFBHCBUDBRR-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000012860 organic pigment Substances 0.000 description 2
- BWOROQSFKKODDR-UHFFFAOYSA-N oxobismuth;hydrochloride Chemical compound Cl.[Bi]=O BWOROQSFKKODDR-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 230000021148 sequestering of metal ion Effects 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000437 stratum spinosum Anatomy 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VRUOTYGNKCHBJA-GRKSLAKBSA-N (2R,4R)-3-[(2R,3R,4R,5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxypentane-1,2,4,5-tetrol Chemical compound OC[C@@H](O)C(O[C@@H]1O[C@@H]([C@H](O)CO)[C@H](O)[C@H]1O)[C@H](O)CO VRUOTYGNKCHBJA-GRKSLAKBSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical class C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- BJDAUCLANVMIOB-UHFFFAOYSA-N (3-decanoyloxy-2,2-dimethylpropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCCCC BJDAUCLANVMIOB-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 description 1
- ORTVZLZNOYNASJ-UPHRSURJSA-N (z)-but-2-ene-1,4-diol Chemical compound OC\C=C/CO ORTVZLZNOYNASJ-UPHRSURJSA-N 0.000 description 1
- FCAXDVKLWVSHGT-KVVVOXFISA-N (z)-docos-13-enoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O FCAXDVKLWVSHGT-KVVVOXFISA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 description 1
- CUVLMZNMSPJDON-UHFFFAOYSA-N 1-(1-butoxypropan-2-yloxy)propan-2-ol Chemical compound CCCCOCC(C)OCC(C)O CUVLMZNMSPJDON-UHFFFAOYSA-N 0.000 description 1
- GDXHBFHOEYVPED-UHFFFAOYSA-N 1-(2-butoxyethoxy)butane Chemical compound CCCCOCCOCCCC GDXHBFHOEYVPED-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- RWNUSVWFHDHRCJ-UHFFFAOYSA-N 1-butoxypropan-2-ol Chemical compound CCCCOCC(C)O RWNUSVWFHDHRCJ-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- RRQYJINTUHWNHW-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
- CNJRPYFBORAQAU-UHFFFAOYSA-N 1-ethoxy-2-(2-methoxyethoxy)ethane Chemical compound CCOCCOCCOC CNJRPYFBORAQAU-UHFFFAOYSA-N 0.000 description 1
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 description 1
- LIPRQQHINVWJCH-UHFFFAOYSA-N 1-ethoxypropan-2-yl acetate Chemical compound CCOCC(C)OC(C)=O LIPRQQHINVWJCH-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- IFBDFMPSOCGRKA-UHFFFAOYSA-N 1-octadecoxyoctadecane;phosphoric acid Chemical compound OP(O)(O)=O.CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC IFBDFMPSOCGRKA-UHFFFAOYSA-N 0.000 description 1
- QWWTXMUURQLKOT-UHFFFAOYSA-N 1-phenoxypropan-2-yl acetate Chemical compound CC(=O)OC(C)COC1=CC=CC=C1 QWWTXMUURQLKOT-UHFFFAOYSA-N 0.000 description 1
- DMFAHCVITRDZQB-UHFFFAOYSA-N 1-propoxypropan-2-yl acetate Chemical compound CCCOCC(C)OC(C)=O DMFAHCVITRDZQB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical class C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- RKJGFHYCZPZJPE-UHFFFAOYSA-N 2,2-bis(16-methylheptadecanoyloxymethyl)butyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(CC)(COC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C RKJGFHYCZPZJPE-UHFFFAOYSA-N 0.000 description 1
- JNAYPSWVMNJOPQ-UHFFFAOYSA-N 2,3-bis(16-methylheptadecanoyloxy)propyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCCC(C)C JNAYPSWVMNJOPQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- XFBOJHLYDJZYSP-UHFFFAOYSA-N 2,8-dioxoadenine Chemical compound N1C(=O)N=C2NC(=O)NC2=C1N XFBOJHLYDJZYSP-UHFFFAOYSA-N 0.000 description 1
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 1
- VXQBJTKSVGFQOL-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethyl acetate Chemical compound CCCCOCCOCCOC(C)=O VXQBJTKSVGFQOL-UHFFFAOYSA-N 0.000 description 1
- MTVLEKBQSDTQGO-UHFFFAOYSA-N 2-(2-ethoxypropoxy)propan-1-ol Chemical compound CCOC(C)COC(C)CO MTVLEKBQSDTQGO-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- CUDYYMUUJHLCGZ-UHFFFAOYSA-N 2-(2-methoxypropoxy)propan-1-ol Chemical compound COC(C)COC(C)CO CUDYYMUUJHLCGZ-UHFFFAOYSA-N 0.000 description 1
- FEVQEKNYIKQVIR-UHFFFAOYSA-N 2-(2-methylhexoxy)ethanol Chemical compound CCCCC(C)COCCO FEVQEKNYIKQVIR-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NCHBYORVPVDWBJ-UHFFFAOYSA-N 2-(3-methylbutoxy)ethanol Chemical compound CC(C)CCOCCO NCHBYORVPVDWBJ-UHFFFAOYSA-N 0.000 description 1
- MXVBVDSNBADJOC-UHFFFAOYSA-N 2-(4,5-dihydroimidazol-1-yl)-4-hydroxybutanoic acid;sodium Chemical compound [Na].OCCC(C(O)=O)N1CCN=C1 MXVBVDSNBADJOC-UHFFFAOYSA-N 0.000 description 1
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- WFSMVVDJSNMRAR-UHFFFAOYSA-N 2-[2-(2-ethoxyethoxy)ethoxy]ethanol Chemical compound CCOCCOCCOCCO WFSMVVDJSNMRAR-UHFFFAOYSA-N 0.000 description 1
- LNCJHVLXANMHHD-UHFFFAOYSA-N 2-[2-heptadecyl-1-(2-hydroxyethyl)-4,5-dihydroimidazol-1-ium-1-yl]acetate Chemical compound CCCCCCCCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O LNCJHVLXANMHHD-UHFFFAOYSA-N 0.000 description 1
- GNCOVOVCHIHPHP-UHFFFAOYSA-N 2-[[4-[4-[(1-anilino-1,3-dioxobutan-2-yl)diazenyl]-3-chlorophenyl]-2-chlorophenyl]diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC(C(=C1)Cl)=CC=C1C(C=C1Cl)=CC=C1N=NC(C(C)=O)C(=O)NC1=CC=CC=C1 GNCOVOVCHIHPHP-UHFFFAOYSA-N 0.000 description 1
- ZCOLQXXFCPFSNU-UHFFFAOYSA-N 2-[methyl(tetradecanoyl)amino]ethanesulfonic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCC(=O)N(C)CCS(O)(=O)=O ZCOLQXXFCPFSNU-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- MSFSPUZXLOGKHJ-PGYHGBPZSA-N 2-amino-3-O-[(R)-1-carboxyethyl]-2-deoxy-D-glucopyranose Chemical compound OC(=O)[C@@H](C)O[C@@H]1[C@@H](N)C(O)O[C@H](CO)[C@H]1O MSFSPUZXLOGKHJ-PGYHGBPZSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- NQBXSWAWVZHKBZ-UHFFFAOYSA-N 2-butoxyethyl acetate Chemical compound CCCCOCCOC(C)=O NQBXSWAWVZHKBZ-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- SVONRAPFKPVNKG-UHFFFAOYSA-N 2-ethoxyethyl acetate Chemical compound CCOCCOC(C)=O SVONRAPFKPVNKG-UHFFFAOYSA-N 0.000 description 1
- SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
- UPGSWASWQBLSKZ-UHFFFAOYSA-N 2-hexoxyethanol Chemical compound CCCCCCOCCO UPGSWASWQBLSKZ-UHFFFAOYSA-N 0.000 description 1
- JVXJFNLEXLGQIO-UHFFFAOYSA-N 2-hexyldecyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC JVXJFNLEXLGQIO-UHFFFAOYSA-N 0.000 description 1
- OGJDIJKJFYOENF-UHFFFAOYSA-N 2-hexyldecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCC)CCCCCCCC OGJDIJKJFYOENF-UHFFFAOYSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- WHFKYDMBUMLWDA-UHFFFAOYSA-N 2-phenoxyethyl acetate Chemical compound CC(=O)OCCOC1=CC=CC=C1 WHFKYDMBUMLWDA-UHFFFAOYSA-N 0.000 description 1
- CUZKCNWZBXLAJX-UHFFFAOYSA-N 2-phenylmethoxyethanol Chemical compound OCCOCC1=CC=CC=C1 CUZKCNWZBXLAJX-UHFFFAOYSA-N 0.000 description 1
- HCGFUIQPSOCUHI-UHFFFAOYSA-N 2-propan-2-yloxyethanol Chemical compound CC(C)OCCO HCGFUIQPSOCUHI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- DMICIZVPSKKBDO-UHFFFAOYSA-N 3-methylidenepiperidine Chemical compound C=C1CCCNC1 DMICIZVPSKKBDO-UHFFFAOYSA-N 0.000 description 1
- GBSGXZBOFKJGMG-UHFFFAOYSA-N 3-propan-2-yloxypropan-1-ol Chemical compound CC(C)OCCCO GBSGXZBOFKJGMG-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 1
- ZQXRINMCMHCYBD-UHFFFAOYSA-N 4-(2-ethylhexoxy)-4-oxobutanoic acid Chemical compound CCCCC(CC)COC(=O)CCC(O)=O ZQXRINMCMHCYBD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- MVJSIAIXMFGVSA-UHFFFAOYSA-N 6-(2-hexyldecoxy)-6-oxohexanoic acid Chemical compound CCCCCCCCC(CCCCCC)COC(=O)CCCCC(O)=O MVJSIAIXMFGVSA-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- GZVHEAJQGPRDLQ-UHFFFAOYSA-N 6-phenyl-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C=CC=CC=2)=N1 GZVHEAJQGPRDLQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 244000058871 Echinochloa crus-galli Species 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- 102100037644 Kelch-like protein 41 Human genes 0.000 description 1
- 108050003242 Kelch-like protein 41 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DHVFOXMCSA-N L-galactose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-DHVFOXMCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-JFNONXLTSA-N L-mannopyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-JFNONXLTSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ZAQJHHRNXZUBTE-WVZVXSGGSA-N L-xylulose Chemical compound OC[C@H](O)[C@@H](O)C(=O)CO ZAQJHHRNXZUBTE-WVZVXSGGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000017822 Melilotus officinalis Nutrition 0.000 description 1
- 240000000366 Melilotus officinalis Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000596467 Ononis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001278834 Rosa stellata Species 0.000 description 1
- 235000012253 Rosa stellata subsp abyssa Nutrition 0.000 description 1
- 235000007072 Rosa stellata subsp mirifica Nutrition 0.000 description 1
- 235000001634 Rosa stellata subsp stellata Nutrition 0.000 description 1
- 235000004483 Rosa stellata var. erlansoniae Nutrition 0.000 description 1
- 235000010976 Rosa stellata var. mirifica Nutrition 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 235000002953 Saxifraga stolonifera Nutrition 0.000 description 1
- 244000288377 Saxifraga stolonifera Species 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 229920002359 Tetronic® Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- LNRUEZIDUKQGRH-UHFFFAOYSA-N Umbelliferose Natural products OC1C(O)C(CO)OC1(CO)OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 LNRUEZIDUKQGRH-UHFFFAOYSA-N 0.000 description 1
- YUSNDFRUEQZBJG-UHFFFAOYSA-N Umbilicin Natural products OCC(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C1O YUSNDFRUEQZBJG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- XKMYWNHZAQUEPY-YZGJEOKZSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 12-hydroxyoctadecanoate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC(O)CCCCCC)C1 XKMYWNHZAQUEPY-YZGJEOKZSA-N 0.000 description 1
- RJDOZRNNYVAULJ-UHFFFAOYSA-L [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[F-].[F-].[Mg++].[Mg++].[Mg++].[Al+3].[Si+4].[Si+4].[Si+4].[K+] RJDOZRNNYVAULJ-UHFFFAOYSA-L 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- KVXNKFYSHAUJIA-UHFFFAOYSA-N acetic acid;ethoxyethane Chemical compound CC(O)=O.CCOCC KVXNKFYSHAUJIA-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- PYMYPHUHKUWMLA-YUPRTTJUSA-N aldehydo-L-lyxose Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-YUPRTTJUSA-N 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- 150000001304 aldoheptoses Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940072049 amyl acetate Drugs 0.000 description 1
- PGMYKACGEOXYJE-UHFFFAOYSA-N anhydrous amyl acetate Natural products CCCCCOC(C)=O PGMYKACGEOXYJE-UHFFFAOYSA-N 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229910052916 barium silicate Inorganic materials 0.000 description 1
- HMOQPOVBDRFNIU-UHFFFAOYSA-N barium(2+);dioxido(oxo)silane Chemical compound [Ba+2].[O-][Si]([O-])=O HMOQPOVBDRFNIU-UHFFFAOYSA-N 0.000 description 1
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HGKOWIQVWAQWDS-UHFFFAOYSA-N bis(16-methylheptadecyl) 2-hydroxybutanedioate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CC(O)C(=O)OCCCCCCCCCCCCCCCC(C)C HGKOWIQVWAQWDS-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001055 blue pigment Substances 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- HRBZRZSCMANEHQ-UHFFFAOYSA-L calcium;hexadecanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O HRBZRZSCMANEHQ-UHFFFAOYSA-L 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 108010015046 cell aggregation factors Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 229910000152 cobalt phosphate Inorganic materials 0.000 description 1
- LFSBSHDDAGNCTM-UHFFFAOYSA-N cobalt(2+);oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[O-2].[Ti+4].[Co+2] LFSBSHDDAGNCTM-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940019778 diethylene glycol diethyl ether Drugs 0.000 description 1
- 229940028356 diethylene glycol monobutyl ether Drugs 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 229940031769 diisobutyl adipate Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- REZZEXDLIUJMMS-UHFFFAOYSA-M dimethyldioctadecylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC REZZEXDLIUJMMS-UHFFFAOYSA-M 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical compound [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- 239000004664 distearyldimethylammonium chloride (DHTDMAC) Substances 0.000 description 1
- JZKFHQMONDVVNF-UHFFFAOYSA-N dodecyl sulfate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(O)(=O)=O JZKFHQMONDVVNF-UHFFFAOYSA-N 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000816 ethylene group Polymers [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229960005082 etohexadiol Drugs 0.000 description 1
- 229910052587 fluorapatite Inorganic materials 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- 229940005740 hexametaphosphate Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 1
- 229910052900 illite Inorganic materials 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 229960005436 inositol nicotinate Drugs 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- JCDAAXRCMMPNBO-UHFFFAOYSA-N iron(3+);oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Ti+4].[Ti+4].[Fe+3].[Fe+3] JCDAAXRCMMPNBO-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940071085 lauroyl glutamate Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UVNRLSCOYBEJTM-UHFFFAOYSA-N linolenic alcohol Natural products CCCCCCCCC=C/CC=C/CC=C/CCO UVNRLSCOYBEJTM-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- 229920006173 natural rubber latex Polymers 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- VGIBGUSAECPPNB-UHFFFAOYSA-L nonaaluminum;magnesium;tripotassium;1,3-dioxido-2,4,5-trioxa-1,3-disilabicyclo[1.1.1]pentane;iron(2+);oxygen(2-);fluoride;hydroxide Chemical compound [OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[F-].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[K+].[K+].[K+].[Fe+2].O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2 VGIBGUSAECPPNB-UHFFFAOYSA-L 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- NPKKRSHVJIQBKU-UHFFFAOYSA-N ornogenin Natural products CC(OC(=O)C=Cc1ccccc1)C2(O)CCC3(O)C4(O)CC=C5CC(O)CCC5(C)C4CC(OC(=O)C=Cc6ccccc6)C23C NPKKRSHVJIQBKU-UHFFFAOYSA-N 0.000 description 1
- JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical compound O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- ONQDVAFWWYYXHM-UHFFFAOYSA-M potassium lauryl sulfate Chemical compound [K+].CCCCCCCCCCCCOS([O-])(=O)=O ONQDVAFWWYYXHM-UHFFFAOYSA-M 0.000 description 1
- 229940116985 potassium lauryl sulfate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- LLHKCFNBLRBOGN-UHFFFAOYSA-N propylene glycol methyl ether acetate Chemical compound COCC(C)OC(C)=O LLHKCFNBLRBOGN-UHFFFAOYSA-N 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000001057 purple pigment Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- KMPHTYSTEHXSTL-UHFFFAOYSA-M sodium;2-hydroxypropanoate;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O.CC(O)C([O-])=O KMPHTYSTEHXSTL-UHFFFAOYSA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940071136 stearoyl glutamate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000498 stratum granulosum Anatomy 0.000 description 1
- 229910052917 strontium silicate Inorganic materials 0.000 description 1
- QSQXISIULMTHLV-UHFFFAOYSA-N strontium;dioxido(oxo)silane Chemical compound [Sr+2].[O-][Si]([O-])=O QSQXISIULMTHLV-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940117986 sulfobetaine Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- KWXLCDNSEHTOCB-UHFFFAOYSA-J tetrasodium;1,1-diphosphonatoethanol Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P(=O)([O-])C(O)(C)P([O-])([O-])=O KWXLCDNSEHTOCB-UHFFFAOYSA-J 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- JLGLQAWTXXGVEM-UHFFFAOYSA-N triethylene glycol monomethyl ether Chemical compound COCCOCCOCCO JLGLQAWTXXGVEM-UHFFFAOYSA-N 0.000 description 1
- SCRSFLUHMDMRFP-UHFFFAOYSA-N trimethyl-(methyl-octyl-trimethylsilyloxysilyl)oxysilane Chemical compound CCCCCCCC[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C SCRSFLUHMDMRFP-UHFFFAOYSA-N 0.000 description 1
- 229940118594 trimethylolpropane triisostearate Drugs 0.000 description 1
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- SVETUDAIEHYIKZ-IUPFWZBJSA-N tris[(z)-octadec-9-enyl] phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOP(=O)(OCCCCCCCC\C=C/CCCCCCCC)OCCCCCCCC\C=C/CCCCCCCC SVETUDAIEHYIKZ-IUPFWZBJSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- LNRUEZIDUKQGRH-YZUCMPLFSA-N umbelliferose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 LNRUEZIDUKQGRH-YZUCMPLFSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 239000009538 yokuinin Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 229940105125 zinc myristate Drugs 0.000 description 1
- GBFLQPIIIRJQLU-UHFFFAOYSA-L zinc;tetradecanoate Chemical compound [Zn+2].CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O GBFLQPIIIRJQLU-UHFFFAOYSA-L 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Cosmetics (AREA)
Description
本発明は、化粧料基剤のスクリーニング方法に関する。 The present invention relates to a method for screening a cosmetic base.
化粧料等の皮膚外用剤の基剤としては、さまざまな配合成分や剤型のものがある。
基剤は、通常は有効成分を抱えるマトリックスの役割を担ったり、あるいは肌への適用時になめらかさやさっぱり感等の感触を演出する役割を果たしたりするものである。すなわち、それ自体に肌への作用効果を期待されるものではない。
As the base of external preparations for skin such as cosmetics, there are various compounding ingredients and dosage forms.
The base usually plays the role of a matrix holding the active ingredient, or plays a role of producing a feeling such as smoothness and refreshing feeling when applied to the skin. That is, it is not expected to have an effect on the skin by itself.
化粧料の主要な剤型のひとつに、水中油(O/W)乳化剤型がある。これは、分散相が油で、連続相が水からなるエマルションからなる。一般にエマルションの性質は、連続相の性質が強く表れるため、水中油型エマルションは水に溶解し、延びがよく、さっぱりとした使用感の化粧料が得られる。そのため、乳液やクリーム等、化粧料の基剤として広く用いられている。 One of the main dosage forms of cosmetics is the oil-in-water (O / W) emulsifier type. It consists of an emulsion in which the dispersed phase is oil and the continuous phase is water. In general, since the properties of emulsions strongly show the properties of continuous phases, oil-in-water emulsions dissolve in water, spread well, and provide cosmetics with a refreshing feel. Therefore, it is widely used as a base for cosmetics such as milky lotions and creams.
ところで、健康な肌は、角層細胞間に細胞間脂質を抱える隙間があり、角層が籠状になっている(非特許文献1)。そのような状態は、バスケットウィーブ(Basket w
eave)角層とも呼ばれる。一方、皮膚炎や乾皮症等で異常な肌では、角層細胞間に隙間がなく接着した状態(コンパクト角層)となっている。
コンパクト角層では角層細胞全表面に細胞接着因子が存在し、角層細胞同士が面で強固に接着しているのに対し、バスケットウィーブ角層では角層細胞の辺縁部にのみ細胞接着因子が存在し、角層細胞の端同士で接着する結果間隙を形成することが分かっている(非特許文献2〜3)。これを利用して、被験者から剥離・採取した角層試料から細胞接着因子を検出して、表皮ターンオーバーや肌状態を評価することが開示されている(特許文献1)。
By the way, in healthy skin, there are gaps between cells of the stratum corneum that hold intercellular lipids, and the stratum corneum has a cage shape (Non-Patent Document 1). Such a state is a basket weave (Basket w)
eave) Also called the stratum corneum. On the other hand, in abnormal skin due to dermatitis, xerosis, etc., the stratum corneum cells are in a state of being adhered without gaps (compact stratum corneum).
In the compact stratum corneum, cell adhesion factors are present on the entire surface of the stratum corneum cells, and the stratum corneum cells adhere firmly to each other on the surface, whereas in the basket weave stratum corneum, the cells adhere only to the margins of the stratum corneum cells. It is known that a factor exists and forms a gap as a result of adhesion between the ends of stratum corneum cells (Non-Patent Documents 2 and 3). It is disclosed that cell adhesion factor is detected from a stratum corneum sample exfoliated and collected from a subject to evaluate epidermal turnover and skin condition (Patent Document 1).
前述のように、従来、基剤にはマトリックスの役割や使用感触を演出する役割が求められており、それ自体に肌への作用効果を期待されてこなかった。
しかしながら、化粧料の基剤自体が肌への作用効果を奏するのであれば単なるマトリックスではなく付加価値のあるものとなる。また、肌への作用として肌状態改善作用がある基剤を採用できれば、化粧料の処方設計の幅が広がる。
このような状況に鑑みて、本発明は、それ自体が肌状態改善作用を発揮し、肌状態改善用途に適する化粧料基剤を提供することを課題とする。また、かかる基剤を探索するに当たり、非侵襲的で簡便なスクリーニング方法を提供することをも課題とする。
As described above, conventionally, the base has been required to have a role of a matrix and a role of producing a feeling of use, and it has not been expected to have an action effect on the skin by itself.
However, if the base of the cosmetic itself has an effect on the skin, it is not a mere matrix but has added value. In addition, if a base having a skin condition improving action can be adopted as an action on the skin, the range of prescription design of cosmetics will be expanded.
In view of such a situation, it is an object of the present invention to provide a cosmetic base which itself exerts a skin condition improving effect and is suitable for skin condition improving applications. Further, in searching for such a base, it is also an object to provide a non-invasive and simple screening method.
本発明者らは上記課題を解決するために鋭意研究を行った結果、水中油型エマルションが、皮膚においてバスケットウィーブ状の角層形成を促し、そのような皮膚では角層水分量、皮膚柔軟性、肌色改善、成分貯留・浸透性向上、キメ等の肌状態が改善されることを見出し、肌状態改善用化粧料基剤に係る本発明を完成するに至った。
また、本発明者らは、三次元培養皮膚モデルでは、正常な皮膚と異なり、バスケット角層の形成が認められないが、水中油型エマルションを適用すると、培養初期に密につまった状態の角層からバスケットウィーブ角層の形成が促進され、正常な皮膚に近い角層構造をもつ皮膚モデルになることを見出し、スクリーニング方法に係る本発明をも完成するに至った。
As a result of diligent research to solve the above problems, the present inventors promoted the formation of basket weave-like stratum corneum in the skin, and in such skin, the stratum corneum water content and skin flexibility. , It has been found that the skin condition such as skin color improvement, component storage / permeability improvement, and texture is improved, and the present invention relating to a cosmetic base for skin condition improvement has been completed.
In addition, unlike normal skin, the present inventors did not observe the formation of basket stratum corneum in the three-dimensional cultured skin model, but when the oil-in-water emulsion was applied, the corners were densely packed at the initial stage of culture. It has been found that the formation of the basket weave stratum corneum is promoted from the layer, and the skin model has a stratum corneum structure close to that of normal skin, and the present invention relating to the screening method has also been completed.
すなわち、本発明は以下の通りである。
[1]水中油乳化剤型であることを特徴とする、肌状態改善用化粧料基剤。
[2]多価アルコールを含有することを特徴とする、[1]に記載の肌状態改善用化粧料基剤。
[3]前記肌状態改善が、角層水分量増加、皮膚柔軟性向上、肌色改善、成分貯留・浸透性向上、及びキメ改善からなる群から選択される、[1]又は[2]に記載の肌状態改善用化粧料基剤。
[4][1]〜[3]のいずれかに記載の肌状態改善用化粧料基剤を肌状態改善成分として含有する、化粧料。
[5]培養皮膚におけるバスケットウィーブ(Basket weave)角層形成を指
標とする、肌状態改善用化粧料基剤のスクリーニング方法。
[6]前記バスケットウィーブ角層形成を、前記培養皮膚の断面の観察、又は前記培養皮膚の角層蛋白質の検出により評価する工程を含む、[5]に記載のスクリーニング方法。[7]前記肌状態改善が、角層水分量増加、皮膚柔軟性向上、肌色改善、成分貯留・浸透性向上、及びキメ改善からなる群から選択される、[5]又は[6]に記載のスクリーニング方法。
That is, the present invention is as follows.
[1] A cosmetic base for improving skin condition, which is characterized by being an oil-in-water emulsifier type.
[2] The cosmetic base for improving skin condition according to [1], which contains a polyhydric alcohol.
[3] The improvement of the skin condition is selected from the group consisting of an increase in the amount of water in the stratum corneum, an improvement in skin flexibility, an improvement in skin color, an improvement in component retention / permeability, and an improvement in texture, according to [1] or [2]. Cosmetic base for improving skin condition.
[4] A cosmetic containing the skin condition improving cosmetic base according to any one of [1] to [3] as a skin condition improving ingredient.
[5] A method for screening a cosmetic base for improving skin condition, using the formation of a basket weave stratum corneum in cultured skin as an index.
[6] The screening method according to [5], which comprises a step of evaluating the basket weave stratum corneum formation by observing a cross section of the cultured skin or detecting a stratum corneum protein in the cultured skin. [7] The improvement of the skin condition is selected from the group consisting of an increase in the amount of water in the stratum corneum, an improvement in skin flexibility, an improvement in skin color, an improvement in component retention / permeability, and an improvement in texture, according to [5] or [6]. Screening method.
本発明により、それ自体が肌状態改善作用を発揮する化粧料基剤が提供される。また、肌状態改善用化粧料基剤を、非侵襲的で簡便に探索できるスクリーニング方法が提供される。 INDUSTRIAL APPLICABILITY The present invention provides a cosmetic base that itself exerts a skin condition improving effect. In addition, a screening method that can easily search for a cosmetic base for improving skin condition is provided.
<本発明の肌状態改善用化粧料基剤>
本発明の肌状態改善用化粧料基剤は、水中油乳化剤型であることを特徴とする。
ここで、水中油乳化剤型は単純なO/W型エマルションに限らず、(O1+O2)/W型や(W/O)/W型等の複合エマルションでもよい。
また、そのエマルション粒子は、特に限定されないが、0.1〜10μmの平均粒子径のものが、バスケットウィーブ角層形成能に優れ、良好な肌状態改善効果が得られるため好ましい。
<Cosmetic base for improving skin condition of the present invention>
The cosmetic base for improving skin condition of the present invention is characterized by being an oil-in-water emulsifier type.
Here, the oil emulsifier type in water is not limited to a simple O / W type emulsion, and may be a composite emulsion such as (O 1 + O 2 ) / W type or (W / O) / W type.
The emulsion particles are not particularly limited, but those having an average particle size of 0.1 to 10 μm are preferable because they have excellent basket weave stratum corneum forming ability and a good skin condition improving effect can be obtained.
本発明の肌状態改善用化粧料基剤は、通常、油相成分、水相成分、及び界面活性剤を含む処方で構成される。
油相成分は通常油性成分で構成され、油性成分はいわゆる油剤に限らず、25〜65℃の水に懸濁して1時間静置した後に水と相分離する成分(ただし界面活性剤を除く)を指す。
本発明の肌状態改善用化粧料基剤に配合し得る油性成分としては、極性油、非極性油、シリコーン油、天然油脂、炭化水素油等の油剤;紫外線吸収剤、紫外線散乱剤等の紫外線防御剤;ビタミンAやビタミンE等の油溶性ビタミン等が挙げられる。
本発明の肌状態改善用化粧料基剤は、油剤を、基剤全体に対して好ましくは1〜70質量%、より好ましくは3〜50質量%、さらに好ましくは5〜40質量%含有する。このような範囲で油剤を内相に含む水中油乳化剤型であることにより、バスケットウィーブ角層形成能がより高まる。
The cosmetic base for improving skin condition of the present invention is usually composed of a formulation containing an oil phase component, an aqueous phase component, and a surfactant.
The oil phase component is usually composed of an oil component, and the oil component is not limited to a so-called oil agent, but is a component that is suspended in water at 25 to 65 ° C. and allowed to stand for 1 hour and then phase-separated from water (excluding surfactants). Point to.
Oily components that can be blended in the cosmetic base for improving skin condition of the present invention include oils such as polar oils, non-polar oils, silicone oils, natural fats and oils, and hydrocarbon oils; ultraviolet rays such as ultraviolet absorbers and ultraviolet scattering agents. Protective agents: Oil-soluble vitamins such as vitamin A and vitamin E can be mentioned.
The cosmetic base for improving skin condition of the present invention contains an oil agent in an amount of preferably 1 to 70% by mass, more preferably 3 to 50% by mass, still more preferably 5 to 40% by mass, based on the whole base. By using an oil-in-water emulsifier type containing an oil agent in the internal phase in such a range, the basket weave stratum corneum forming ability is further enhanced.
油剤のうち、極性油としては、合成エステル油として、ミリスチン酸イソプロピル、オクタン酸セチル、ミリスチン酸オクチルドデシル、パルミチン酸イソプロピル、ステアリン酸ブチル、ラウリン酸ヘキシル、ミリスチン酸ミリスチル、オレイン酸デシル、ジメチルオクタン酸ヘキシルデシル、乳酸セチル、乳酸ミリスチル、酢酸ラノリン、ステアリン酸イソセチル、イソステアリン酸イソセチル、12−ヒドロキシステアリル酸コレステリル、ジ−2−エチルヘキシル酸エチレングリコール、ジペンタエリスリトール脂肪酸エステル、モノイソステアリン酸N−アルキルグリコール、ジカプリン酸ネオペンチルグリコール、リンゴ酸ジイソステアリル、ジ−2−ヘプチルウンデカン酸グリセリン、トリ−2−エチルヘキシル酸トリメチロールプロパン、トリイソステアリン酸トリメチロールプロパン、テトラ−2−エチルヘキシル酸ペンタンエリスリトール、トリ−2−エチルヘキサン酸グリセリル、トリイソステアリン酸トリメチロールプロパン、セチル2−エチルヘキサノエート、2−エチルヘキシルパルミテート、トリミリスチン酸グリセリン、トリ−2−ヘプチルウンデカン酸グリセライド、ヒマシ油脂肪酸メチルエステル、オレイン酸オイル、セトステアリルアルコール、アセトグリセライド、パルミチン酸2−ヘプチルウンデシル、アジピン酸ジイソブチル、N−ラウロイル−L−グルタミン酸−2−オクチルドデシルエステル、アジピン酸ジ−2−ヘプチルウンデシル、エチルラウレート、セバチン酸ジ−2−エチルヘキシル、ミリスチン酸2−ヘキシルデシル、パルミチン酸2−ヘキシルデシル、アジピン酸2−ヘキシルデシル、セバチン酸ジイソプロピル、コハク酸2−エチルヘキシル、酢酸エチル、酢酸ブチル、酢酸アミル、クエン酸トリエチル、オクチルメトキシシンナメート等が挙げられる。 Among the oils, polar oils include isopropyl myristate, cetyl octanate, octyldodecyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, decyl oleate, and dimethyloctanoic acid. Hexyldecyl, cetyl lactate, myristyl lactate, lanolin acetate, isocetyl stearate, isosetyl isostearate, cholesteryl 12-hydroxystearyl, ethylene glycol di-2-ethylhexylate, dipentaerythritol fatty acid ester, N-alkylglycol monoisostearate, Neopentyl glycol dicaprate, diisostearyl malate, glycerin di-2-heptylundecanoate, trimethylolpropane tri-2-ethylhexylate, trimethylolpropane tri-2-ethylhexylate, pentanerythritol tetra-2-ethylhexylate, tri-2 -Glyceryl ethylhexanate, Trimethylolpropane triisostearate, Cetyl 2-ethylhexanoate, 2-Ethylhexyl palmitate, Glycerin trimyristate, Glyceride tri-2-heptylundecanoic acid, Methyl ester of castor oil fatty acid, Oleic acid oil , Cetostearyl alcohol, acetoglyceride, 2-heptyl undecyl palmitate, diisobutyl adipate, N-lauroyl-L-glutamic acid-2-octyldodecyl ester, di-2-heptyl undecyl adipate, ethyl laurate, sebatic acid Di-2-ethylhexyl, 2-hexyldecyl myristate, 2-hexyldecyl palmitate, 2-hexyldecyl adipate, diisopropyl sebatate, 2-ethylhexyl succinate, ethyl acetate, butyl acetate, amyl acetate, triethyl citrate, Examples thereof include octylmethoxycinnamate.
極性を有しないシリコーン油としてはシクロペンタシロキサン、デカメチルシクロペンタシロキサン、カプリリルメチコン、ジメチコン、(ジメチコン/ビニルジメチコン)クロスポリマー、(ジメチコン/フェニルビニルジメチコン)クロスポリマー等が挙げられる。
極性を有するシリコーン油としてはジフェニルシロキシフェニルトリメチコン等が挙げられる。
天然油脂として、アボカド油、ツバキ油、タートル油、マカデミアナッツ油、トウモロコシ油、ミンク油、オリーブ油、ナタネ油、卵黄油、ゴマ油、パーシック油、小麦胚芽油、サザンカ油、ヒマシ油、アマニ油、サフラワー油、綿実油、エノ油、大豆油、落花生油、茶実油、カヤ油、コメヌカ油、シナギリ油、日本キリ油、ホホバ油、胚芽油、トリグリセリン、トリオクタン酸グリセリン、トリイソパルミチン酸グリセリン等が挙げられる。
炭化水素油としては、イソドデカン、イソヘキサデカン、スクワラン、ワセリン、水添ポリ(C6−12オレフィン)、水添ポリイソブテン等が挙げられる。
Examples of the non-polar silicone oil include cyclopentasiloxane, decamethylcyclopentasiloxane, caprylylmethicone, dimethicone, (dimethicone / vinyldimethicone) crosspolymer, (dimethicone / phenylvinyldimethicone) crosspolymer and the like.
Examples of the polar silicone oil include diphenylsiloxyphenyl trimeticone and the like.
Natural fats and oils include avocado oil, camellia oil, turtle oil, macadamia nut oil, corn oil, mink oil, olive oil, rapeseed oil, egg yolk oil, sesame oil, persic oil, wheat germ oil, southern ka oil, castor oil, flaxseed oil, saflower. Oil, cotton seed oil, eno oil, soybean oil, peanut oil, tea seed oil, kaya oil, rice bran oil, cinnamon oil, Japanese millet oil, jojoba oil, germ oil, triglycerin, glycerin trioctanoate, glycerin triisopalmitate, etc. Can be mentioned.
Examples of the hydrocarbon oil include isododecane, isohexadecane, squalane, petrolatum, hydrogenated poly (C6-12 olefin), hydrogenated polyisobutene and the like.
水相成分は、水の他に、水溶性成分であれば特に限定されず、例えば、多価アルコールや高級アルコール等が挙げられる。なお、高級アルコールは、炭素数16〜22、好ましくは18〜22のアルコールを指す。 The aqueous phase component is not particularly limited as long as it is a water-soluble component in addition to water, and examples thereof include polyhydric alcohols and higher alcohols. The higher alcohol refers to an alcohol having 16 to 22 carbon atoms, preferably 18 to 22 carbon atoms.
本発明の肌状態改善用化粧料基剤には、前記水相成分のうち多価アルコールを含有することがこのましい。多価アルコールを含有することにより、バスケットウィーブ角層形成能がより高まる。
多価アルコールとしては、2価以上であれば特に限定されないが、3価以上のものが好ましい。具体的には、2価のアルコール(例えば、エチレングリコール、プロピレングリコール、トリメチレングリコール、1,2−ブチレングリコール、1,3−ブチレングリコール、テトラメチレングリコール、2,3−ブチレングリコール、ペンタメチレングリコール、2−ブテン−1,4−ジオール、ヘキシレングリコール、オクチレングリコール等);3価のアルコール(例えば、グリセリン、トリメチロールプロパン等);4価アルコール(例えば、1,2,6−ヘキサントリオール等のペンタエリスリトール等);5価アルコール(例えば、キシリトール等);6価アルコール(例えば、ソルビトール、マンニトール等);多価アルコール重合体(例えば、ジエチレングリコール、ジプロピレングリコール、トリエチレングリコール、ポリプロピレングリコール、テトラエチレングリコール、ジグリセリン、ポリエチレングリコール、トリグリセリン、テトラグリセリン、ポリグリセリン等);2価のアルコールアルキルエーテル類(例えば、エチレングリコールモノメチルエーテル、エチレングリコールモノエチルエーテル、エチレングリコールモノブチルエーテル、エチレングリコールモノフェニルエーテル、エチレングリコールモノヘキシルエーテル、エチレングリコールモノ2−メチルヘキシルエーテル、エチレングリコールイソアミルエーテル、エチレングリコールベンジルエーテル、エチレングリコールイソプロピルエーテル、エチレングリコールジメチルエーテル、エチレングリコールジエチルエーテル、エチレングリコールジブチルエーテル等);2価アルコールアルキルエーテル類(例えば、ジエチレングリコールモノメチルエーテル、ジエチレングリコールモノエチルエーテル、ジエチレングリコールモノブチルエーテル、ジエチレングリコールジメチルエーテル、ジエチレングリコールジエチルエーテル、ジエチレングリコールブチルエーテル、ジエチレングリコールメチルエチルエーテル、トリエチレングリコールモノメチルエーテル、トリエチレングリコールモノエチルエーテル、プロピレングリコールモノメチルエーテル、プロピレングリコールモノエチルエーテル、プロピレングリコールモノブチルエーテル、プロピレングリコールイソプロピルエーテル、ジプロピレングリコールメチルエーテル、ジプロピレングリコールエチルエーテル、ジプロピレングリコールブチルエーテル等);2価アルコールエーテルエステル(例えば、エチレングリコールモノメチルエーテルアセテート、エチレングリコールモノエチルエーテルアセテート、エチレングリコールモノブチルエーテルアセテート、エチレングリコールモノフェニルエーテルアセテート、エチレングリコールジアジベート、エチレングリコールジサクシネート、ジエチレングリコールモノエチルエーテルアセテート、ジエチレングリコールモノブチルエーテルアセテート、プロピレングリコールモノメチルエーテルアセテート、プロピレングリコールモノエチルエーテルアセテート、プロピレングリコールモノプロピルエーテルアセテート、プロピレングリコールモノフェニルエーテルアセテート等);グリセリンモノアルキルエーテル(例えば、キシルアルコール、セラキルアルコール、バチルアルコール等);
糖アルコール(例えば、ソルビトール、マルチトール、マルトトリオース、マンニトール、ショ糖、エリトリトール、グルコース、フルクトース、デンプン分解糖、マルトース、キシリトース、デンプン分解糖還元アルコール等);グリソリッド;テトラハイドロフルフリルアルコール;POE−テトラハイドロフルフリルアルコール;POP−ブチルエーテル;POP・POE−ブチルエーテル;トリポリオキシプロピレングリセリンエーテル;POP−グリセリンエーテル;POP−グリセリンエーテルリン酸;POP・POE−ペンタンエリスリトールエーテル等が挙げられ、これらの一種又は二種以上を組み合わせることができる。
これらのうち、グリセリン、ジグリセリン、ジプロピレングリコール、分子量600以下のポリエチレングリコールがより好ましい。
本発明の肌状態改善用化粧料基剤は、多価アルコールを、基剤全体に対して好ましくは1〜40質量%、より好ましくは5〜40質量%、さらに好ましくは10〜30質量%、特に好ましくは15〜30質量%含有する。
The cosmetic base for improving skin condition of the present invention preferably contains a polyhydric alcohol among the aqueous phase components. By containing the polyhydric alcohol, the basket weave stratum corneum forming ability is further enhanced.
The polyhydric alcohol is not particularly limited as long as it is divalent or higher, but trihydric or higher is preferable. Specifically, divalent alcohols (eg, ethylene glycol, propylene glycol, trimethylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, tetramethylene glycol, 2,3-butylene glycol, pentamethylene glycol). , 2-Buten-1,4-diol, hexylene glycol, octylene glycol, etc.; trivalent alcohol (eg, glycerin, trimethylolpropane, etc.); tetravalent alcohol (eg, 1,2,6-hexanetriol, etc.) Etc. Pentaerythritol, etc.); pentavalent alcohol (eg, xylitol, etc.); hexavalent alcohol (eg, sorbitol, mannitol, etc.); polyhydric alcohol polymer (eg, diethylene glycol, dipropylene glycol, triethylene glycol, polypropylene glycol, etc.) Tetraethylene glycol, diglycerin, polyethylene glycol, triglycerin, tetraglycerin, polyglycerin, etc.); divalent alcohol alkyl ethers (eg, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, ethylene glycol mono) Phenyl ether, ethylene glycol monohexyl ether, ethylene glycol mono2-methylhexyl ether, ethylene glycol isoamyl ether, ethylene glycol benzyl ether, ethylene glycol isopropyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, ethylene glycol dibutyl ether, etc.); 2 Valuable alcohol alkyl ethers (eg, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, diethylene glycol butyl ether, diethylene glycol methyl ethyl ether, triethylene glycol monomethyl ether, triethylene glycol monoethyl ether, propylene Glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol monobutyl ether, propylene glycol isopropyl ether, dipropylene glycol methyl ether, dipropylene glycol ethyl ether, dipropylene glycol butyl ether, etc. ); Divalent alcohol ether ester (eg, ethylene glycol monomethyl ether acetate, ethylene glycol monoethyl ether acetate, ethylene glycol monobutyl ether acetate, ethylene glycol monophenyl ether acetate, ethylene glycol diazibate, ethylene glycol dissuccinate, diethylene glycol mono). Ethyl ether acetate, diethylene glycol monobutyl ether acetate, propylene glycol monomethyl ether acetate, propylene glycol monoethyl ether acetate, propylene glycol monopropyl ether acetate, propylene glycol monophenyl ether acetate, etc.); Alcohol, batyl alcohol, etc.);
Sugar alcohols (eg, sorbitol, martitol, maltotriose, mannitol, sucrose, erythritol, glucose, fructose, starch-degrading sugar, maltose, xylitos, starch-degrading sugar-reducing alcohol, etc.); glyceroli; tetrahydrofurfuryl alcohol; POE-tetrahydrofurfuryl alcohol; POP-butyl ether; POP / POE-butyl ether; tripolyoxypropylene glycerin ether; POP-glycerin ether; POP-glycerin ether phosphoric acid; POP / POE-pentaneerythritol ether and the like. One type or a combination of two or more types can be combined.
Of these, glycerin, diglycerin, dipropylene glycol, and polyethylene glycol having a molecular weight of 600 or less are more preferable.
The cosmetic base for improving skin condition of the present invention contains a polyhydric alcohol in an amount of preferably 1 to 40% by mass, more preferably 5 to 40% by mass, still more preferably 10 to 30% by mass, based on the whole base. Particularly preferably, it contains 15 to 30% by mass.
高級アルコールは、通常は脂肪族アルコールであり、分岐はあってもなくてもよく、飽和又は不飽和のいずれでもよい。また、好ましくは一価のアルコールである。例えば、バチルアルコール、セタノール、パルミトレイルアルコール、ヘプタデカノール、1−ヘプタデカノール、ステアリルアルコール、イソステアリルアルコール、エライジルアルコール、オレイルアルコール、リノレイルアルコール、エライドリノレイルアルコール、リノレニルアルコール、エライドリノレニルアルコール、リシノレイルアルコール、ノナデシルアルコール、アラキジルアルコール、ヘンエイコサノール、ベヘニルアルコール、及びエルシルアルコールが挙げられ、ベヘニルアルコール、ステアリルアルコール、アラキジルアルコールが特に好ましい。なお、これらの一種又は二種以上を組み合わせることができる。
本発明の肌状態改善用化粧料基剤は、高級アルコールを、基剤全体に対して好ましくは0〜5質量%、より好ましくは0.1〜5質量%、さらに好ましくは0.5〜3質量%含有する。
The higher alcohol is usually an aliphatic alcohol, which may or may not be branched and may be saturated or unsaturated. Also, it is preferably a monohydric alcohol. For example, bacil alcohol, setanol, palmitrail alcohol, heptadecanol, 1-heptadecanol, stearyl alcohol, isostearyl alcohol, ellaidyl alcohol, oleyl alcohol, linoleil alcohol, elelide linoleil alcohol, linolenyl alcohol, Elyde linolenic alcohol, ricinorail alcohol, nonadecil alcohol, arachidyl alcohol, heneicosanol, behenyl alcohol, and elcil alcohol are mentioned, and behenyl alcohol, stearyl alcohol, and arachidyl alcohol are particularly preferable. In addition, these one kind or two or more kinds can be combined.
The cosmetic base for improving skin condition of the present invention contains a higher alcohol, preferably 0 to 5% by mass, more preferably 0.1 to 5% by mass, still more preferably 0.5 to 3% by mass, based on the whole base. Contains% by mass.
界面活性剤は、アニオン界面活性剤、カチオン界面活性剤、両性界面活性剤、非イオン性界面活性剤、シリコーン系界面活性剤等が挙げられ、特に限定されない。
本発明の肌状態改善用化粧料基剤は、界面活性剤を、基剤全体に対して好ましくは0.1〜7質量%、より好ましくは0.5〜5質量%、さらに好ましくは1〜5質量%含有する。
Examples of the surfactant include anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, silicone-based surfactants, and the like, and are not particularly limited.
In the cosmetic base for improving skin condition of the present invention, the surfactant is preferably 0.1 to 7% by mass, more preferably 0.5 to 5% by mass, still more preferably 1 to 1% by mass based on the whole base. Contains 5% by mass.
アニオン界面活性剤としては、例えば、脂肪酸セッケン(例えば、ラウリン酸ナトリウム、パルミチン酸ナトリウム等);高級アルキル硫酸エステル塩(例えば、ラウリル硫酸ナトリウム、ラウリル硫酸カリウム等);アルキルエーテル硫酸エステル塩(例えば、POEラウリル硫酸トリエタノールアミン、POEラウリル硫酸ナトリウム等);N−アシルサルコシン酸(例えば、ラウロイルサルコシンナトリウム等);高級脂肪酸アミドスルホン酸塩(例えば、N−ミリストイル−N−メチルタウリンナトリウム、ヤシ油脂肪酸メチルタウリッドナトリウム、ラウリルメチルタウリッドナトリウム等);リン酸エステル塩(POEオレイルエーテルリン酸ナトリウム、POEステアリルエーテルリン酸等);スルホコハク酸塩(例えば、ジ−2−エチルヘキシルスルホコハク酸ナトリウム、モノラウロイルモノエタノールアミドポリオキシエチレンスルホコハク酸ナトリウム、ラウリルポリプロピレングリコールスルホコハク酸ナトリウム等);アルキルベンゼンスルホン酸塩(例えば、リニアドデシルベンゼンスルホン酸ナトリウム、リニアドデシルベンゼンスルホン酸トリエタノールアミン、リニアドデシルベンゼンスルホン酸等);高級脂肪酸エステル硫酸エステル塩(例えば、硬化ヤシ油脂肪酸グリセリン硫酸ナトリウム等);N−アシルグルタミン酸塩(例えば、N−ラウロイルグルタミン酸モノナトリウム、N−ステアロイルグルタミン酸ジナトリウム、N−ミリストイル−L−グルタミン酸モノナトリウ
ム等);硫酸化油(例えば、ロート油等);POEアルキルエーテルカルボン酸;POEアルキルアリルエーテルカルボン酸塩;α−オレフィンスルホン酸塩;高級脂肪酸エステルスルホン酸塩;二級アルコール硫酸エステル塩;高級脂肪酸アルキロールアミド硫酸エステル塩;ラウロイルモノエタノールアミドコハク酸ナトリウム;N−パルミトイルアスパラギン酸ジトリエタノールアミン;カゼインナトリウム等が挙げられる。
Examples of the anionic surfactant include fatty acid sulphates (eg, sodium laurate, sodium palmitate, etc.); higher alkyl sulfates (eg, sodium lauryl sulfate, potassium lauryl sulfate, etc.); alkyl ether sulfates (eg, sodium lauryl sulfate, etc.). POE lauryl sulfate triethanolamine, POE sodium lauryl sulfate, etc.); N-acylsarcosic acid (eg, sodium lauroyl sarcosin, etc.); higher fatty acid amide sulfonate (eg, N-myristoyl-N-methyltaurine sodium, coconut oil fatty acid, etc.) Methyl taurid sodium, lauryl methyl taurid sodium, etc.); Phosphate ester salts (POE oleyl ether phosphate sodium, POE stearyl ether phosphoric acid, etc.); Sulfon succinates (eg, di-2-ethylhexyl sulfosuccinate sodium, monolauroyl, etc.) Monoethanolamide polyoxyethylene sodium sulfosuccinate, sodium lauryl polypropylene glycol sulfosuccinate, etc.); Alkylbenzene sulfonate (eg, sodium linadodecylbenzene sulfonate, linadodecylbenzene sulfonate triethanolamine, linadodecylbenzene sulfonic acid, etc.); Higher fatty acid ester sulfate ester salts (eg, cured coconut oil fatty acid sodium glycerin sulfate, etc.); N-acylglutamate (eg, N-lauroyl glutamate monosodium, N-stearoyl glutamate disodium, N-myristoyl-L-glutamate monosodium) Etc.); Sulfated oil (eg, funnel oil, etc.); POE alkyl ether carboxylic acid; POE alkyl allyl ether sulfonate; α-olefin sulfonate; higher fatty acid ester sulfonate; secondary alcohol sulfate ester salt; higher Examples thereof include fatty acid alkylolamide sulfate ester salt; sodium lauroyl monoethanolamide succinate; N-palmitoyl aspartate ditriethanolamine; sodium caseinate and the like.
カチオン界面活性剤としては、例えば、アルキルトリメチルアンモニウム塩(例えば、塩化ステアリルトリメチルアンモニウム、塩化ラウリルトリメチルアンモニウム等);アルキルピリジニウム塩(例えば、塩化セチルピリジニウム等);塩化ジステアリルジメチルアンモニウムジアルキルジメチルアンモニウム塩;塩化ポリ(N,N’−ジメチル−3
,5−メチレンピペリジニウム);アルキル四級アンモニウム塩;アルキルジメチルベン
ジルアンモニウム塩;アルキルイソキノリニウム塩;ジアルキルモリホニウム塩;POEアルキルアミン;アルキルアミン塩;ポリアミン脂肪酸誘導体;アミルアルコール脂肪酸誘導体;塩化ベンザルコニウム;塩化ベンゼトニウム等が挙げられる。
Examples of the cationic surfactant include alkyltrimethylammonium salts (eg, stearyltrimethylammonium chloride, lauryltrimethylammonium chloride, etc.); alkylpyridinium salts (eg, cetylpyridinium chloride, etc.); distearyldimethylammonium chloride dialkyldimethylammonium salts; Polychloride (N, N'-dimethyl-3
, 5-Methylene piperidinium); alkyl quaternary ammonium salt; alkyldimethylbenzylammonium salt; alkylisoquinolinium salt; dialkylmoriphonium salt; POE alkylamine; alkylamine salt; polyamine fatty acid derivative; amyl alcohol fatty acid derivative Benzalkonium chloride; benzethonium chloride and the like.
両性界面活性剤としては、例えば、イミダゾリン系両性界面活性剤(例えば、2−ウンデシル−N,N,N−(ヒドロキシエチルカルボキシメチル)−2−イミダゾリンナトリウム、2−ココイル−2−イミダゾリニウムヒドロキサイド−1−カルボキシエチロキシ2ナトリウム塩等);ベタイン系界面活性剤(例えば、2−ヘプタデシル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリニウムベタイン、ラウリルジメチルアミノ酢酸ベタイン、アルキルベタイン、アミドベタイン、スルホベタイン等)等が挙げられる。 Examples of the amphoteric tenside include imidazoline-based amphoteric tenside agents (for example, 2-undecyl-N, N, N- (hydroxyethylcarboxymethyl) -2-imidazolin sodium, 2-cocoyl-2-imidazolinium hydroki. Side-1-carboxyethyroxy disodium salt, etc.); Betaine-based surfactants (eg, 2-heptadecyl-N-carboxymethyl-N-hydroxyethyl imidazolinium betaine, lauryldimethylaminoacetic acid betaine, alkyl betaine, amide betaine) , Sulfobetaine, etc.) and the like.
非イオン界面活性剤としては、例えば、ソルビタン脂肪酸エステル類(例えば、ソルビタンモノオレエート、ソルビタンモノステアレート、ソルビタンモノイソステアレート、ソルビタンモノラウレート、ソルビタンモノパルミテート、ソルビタンモノステアレート、ソルビタンセスキオレエート、ソルビタントリオレエート、ペンタ−2−エチルヘキシル酸ジグリセロールソルビタン、テトラ−2−エチルヘキシル酸ジグリセロールソルビタン等);グリセリン脂肪酸類(例えば、モノ綿実油脂肪酸グリセリン、モノエルカ酸グリセリン、セスキオレイン酸グリセリン、モノステアリン酸グリセリン、α,α’−オレイン酸ピログルタミン酸グリセリン、モノステアリン酸グリセリンリンゴ酸等);プロピレングリコール脂肪酸エステル類(例えば、モノステアリン酸プロピレングリコール等);POEヒマシ油・硬化ヒマシ油誘導体(POEヒマシ油、POE硬化ヒマシ油等);グリセリンアルキルエーテル等の親油性のものが挙げられる。
また、親水性のものとして、例えば、ポリグリセリン脂肪酸エステル類(例えば、モノオレイン酸ポリグリセリル、モノステアリン酸ポリグリセリル等);POEソルビタン脂肪酸エステル類(例えば、POEソルビタンモノオレエート、POEソルビタンモノステアレート、POEソルビタンテトラオレエート等);POEソルビット脂肪酸エステル類(例えば、POEソルビットモノラウレート、POEソルビットモノオレエート、POEソルビットペンタオレエート、POEソルビットモノステアレート等);POEグリセリン脂肪酸エステル類(例えば、POEグリセリンモノステアレート、POEグリセリンモノイソステアレート、POEグリセリントリイソステアレート等のPOEモノオレエート等);POE脂肪酸エステル類(例えば、POEジステアレート、POEモノステアレート、POEモノジオレエート、ジステアリン酸エチレングリコール等);POEアルキルエーテル類(例えば、POEラウリルエーテル、POEオレイルエーテル、POEステアリルエーテル、POE−ベヘニルエーテル、POE−2−オクチルドデシルエーテル、POEコレスタノールエーテル等);POEアルキルフェニルエーテル類(例えば、POEノニルフェニルエーテル等);プルロニック型類(例えば、プルロニック等);POE・POPアルキルエーテル類(例えば、POE・POPセチルエーテル、POE・POP−2−デシルテトラデシルエーテル、POE・POPモノブチルエーテル、POE・POP水添ラノリン、POE・POPグリセリンエーテル等);テトラ POE・テトラPOP
エチレンジアミン縮合物類(例えば、テトロニック等);POEヒマシ油硬化ヒマシ油誘導体(例えば、POEヒマシ油、POE硬化ヒマシ油、POE硬化ヒマシ油モノイソステアレート、POE硬化ヒマシ油トリイソステアレート、POE硬化ヒマシ油モノピログルタミン酸モノイソステアリン酸ジエステル、POE硬化ヒマシ油マレイン酸等);POEミツロウ・ラノリン誘導体(例えば、POEソルビットミツロウ等);アルカノールアミド(例えば、ヤシ油脂肪酸ジエタノールアミド、ラウリン酸モノエタノールアミド、脂肪酸イソプロパノールアミド等);POEプロピレングリコール脂肪酸エステル;POEアルキルアミン;POE脂肪酸アミド;ショ糖脂肪酸エステル;アルキルグルコシド;アルキルエトキシジメチルアミンオキシド;トリオレイルリン酸等が挙げられる。
Examples of the nonionic surfactant include sorbitan fatty acid esters (for example, sorbitan monooleate, sorbitan monostearate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesqui). Oleate, sorbitan trioleate, penta-2-ethylhexylate diglycerol sorbitan, tetra-2-ethylhexylate diglycerol sorbitan, etc.); glycerin fatty acids (for example, monocotton seed oil fatty acid glycerin, monoerucate glycerin, sesquioleate glycerin, mono Glycerin stearate, α, α'-glycerin pyroglutamate oleate, glycerin monostearate, malic acid, etc.); propylene glycol fatty acid esters (for example, propylene glycol monostearate, etc.); POE castor oil / cured castor oil derivative (POE) Himasi oil, POE-hardened Himashima oil, etc.); Examples thereof include oil-based substances such as glycerin alkyl ether.
Also, as hydrophilic ones, for example, polyglycerin fatty acid esters (for example, polyglyceryl monooleate, polyglyceryl monostearate, etc.); POE sorbitan fatty acid esters (for example, POE sorbitan monooleate, POE sorbitan monostearate, etc.). POE sorbitan tetraoleate, etc.); POE sorbit fatty acid esters (eg, POE sorbit monolaurate, POE sorbit monooleate, POE sorbit pentaoleate, POE sorbit monostearate, etc.); POE glycerin fatty acid esters (eg, POE glycerin fatty acid esters, etc.) POE glycerin monostearate, POE glycerin monoisostearate, POE monooleate such as POE glycerin triisostearate); POE fatty acid esters (eg, POE distearate, POE monostearate, POE monodiolate, ethylene glycol distearate, etc.) POE alkyl ethers (eg, POE lauryl ether, POE oleyl ether, POE stearyl ether, POE-behenyl ether, POE-2-octyldodecyl ether, POE cholestanol ether, etc.); POE alkylphenyl ethers (eg, POE nonyl) Phenyl ether, etc.); Pluronic type (eg, Pluronic, etc.); POE / POP alkyl ethers (eg, POE / POP cetyl ether, POE / POP-2-decyltetradecyl ether, POE / POP monobutyl ether, POE / POP Hydrogenated lanolin, POE / POP glycerin ether, etc.); Tetra POE / Tetra POP
Ethylenediamine condensates (eg, Tetronic, etc.); POE castor oil hardened castor oil derivatives (eg, POE castor oil, POE hardened castor oil, POE hardened castor oil monoisostearate, POE hardened castor oil triisostearate, POE Hardened castor oil monopyroglutamic acid monoisostearic acid diester, POE hardened castor oil maleic acid, etc.; POE castor lanolin derivatives (eg, POE sorbit honeybee, etc.); alkanolamides (eg, coconut oil fatty acid diethanolamide, lauric acid monoethanolamide, etc.) , Fatty acid isopropanolamide, etc.); POE propylene glycol fatty acid ester; POE alkylamine; POE fatty acid amide; sucrose fatty acid ester; alkyl glucoside; alkyl ethoxydimethylamine oxide; trioleyl phosphate and the like.
本発明の肌状態改善用化粧料基剤は、本発明の効果を損なわない限りにおいて、通常化粧料基剤に用いられる他の成分を任意に配合することができる。かかる任意成分としては、例えば、保湿剤、防腐剤、粉末成分、金属イオン封鎖剤、低級アルコール、単糖、オリゴ糖、多糖、アミノ酸、有機アミン、高分子エマルジョン、pH調整剤、酸化防止剤、有機変性粘土鉱物等が挙げられる。 The cosmetic base for improving skin condition of the present invention may optionally contain other ingredients usually used for a cosmetic base as long as the effects of the present invention are not impaired. Such optional components include, for example, moisturizers, preservatives, powder components, metal ion sequestering agents, lower alcohols, monosaccharides, oligosaccharides, polysaccharides, amino acids, organic amines, polymer emulsions, pH adjusters, antioxidants, etc. Examples include organic modified clay minerals.
保湿剤としては、例えば、ポリエチレングリコール、プロピレングリコール、グリセリン、1,3−ブチレングリコール、キシリトール、ソルビトール、マルチトール、コンドロイチン硫酸、ヒアルロン酸、ムコイチン硫酸、カロニン酸、アテロコラーゲン、コレステリル−12−ヒドロキシステアレート、乳酸ナトリウム、胆汁酸塩、dl−ピロリドンカルボン酸塩、短鎖可溶性コラーゲン、ジグリセリン(EO)PO付加物、イザヨイバラ抽出物、セイヨウノコギリソウ抽出物、メリロート抽出物等が挙げられる。
防腐剤としては、例えば、エチルパラベン、ブチルパラベン等が挙げられる。
Moisturizers include, for example, polyethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, xylitol, sorbitol, martitol, chondroitin sulfate, hyaluronic acid, mucoitin sulfate, caronic acid, atelocollagen, cholesteryl-12-hydroxystearate. , Sodium lactate, bile acid salt, dl-pyrrolidone carboxylate, short chain soluble collagen, diglycerin (EO) PO adduct, Izayoi rose extract, Xylitol extract, melilot extract and the like.
Examples of the preservative include ethylparaben, butylparaben and the like.
粉末成分としては、例えば、無機粉末(例えば、タルク、カオリン、雲母、絹雲母(セ
リサイト)、白雲母、金雲母、合成雲母、紅雲母、黒雲母、パーミキュライト、炭酸マグ
ネシウム、炭酸カルシウム、ケイ酸アルミニウム、ケイ酸バリウム、ケイ酸カルシウム、ケイ酸マグネシウム、ケイ酸ストロンチウム、タングステン酸金属塩、マグネシウム、シリカ、ゼオライト、硫酸バリウム、焼成硫酸カルシウム(焼セッコウ)、リン酸カルシウム、弗素アパタイト、ヒドロキシアパタイト、セラミックパウダー、金属石鹸(例えば、ミ
リスチン酸亜鉛、パルミチン酸カルシウム、ステアリン酸アルミニウム)、窒化ホウ素等
);有機粉末(例えば、ポリアミド樹脂粉末(ナイロン粉末)、ポリエチレン粉末、ポリメタクリル酸メチル粉末、ポリスチレン粉末、スチレンとアクリル酸の共重合体樹脂粉末、ベンゾグアナミン樹脂粉末、ポリ四弗化エチレン粉末、セルロース粉末等);無機白色顔料(例えば、二酸化チタン、酸化亜鉛等);無機赤色系顔料(例えば、酸化鉄(ベンガラ)、チタン酸鉄等);無機褐色系顔料(例えば、γ−酸化鉄等);無機黄色系顔料(例えば、黄酸化鉄、黄土等);無機黒色系顔料(例えば、黒酸化鉄、低次酸化チタン等);無機紫色系顔料(例えば、マンゴバイオレット、コバルトバイオレット等);無機緑色系顔料(例えば、酸化クロム、水酸化クロム、チタン酸コバルト等);無機青色系顔料(例えば、群青、紺青等);パール顔料(例えば、酸化チタンコーテッドマイカ、酸化チタンコーテッドオキシ塩化ビスマス、酸化チタンコーテッドタルク、着色酸化チタンコーテッドマイカ、オキシ塩化ビスマス、魚鱗箔等);金属粉末顔料(例えば、アルミニウムパウダー、カッパーパウダー等);ジルコニウム、バリウム又はアルミニウムレーキ等の有機顔料(例えば、赤色201号、赤色202号、赤色204号、赤色205号、赤色220号、赤色226号、赤色228号、赤色405号、橙色203号、橙色204号、黄色205号、黄色401号、及び青色404号などの有機顔料、赤色3号、赤色104号、赤色106号、赤色227号、赤色230号、赤色401号、赤色505号、橙色205号、黄色4号、黄色5号、黄色202号、黄色203号、緑色3号及び青色1号等);天然色素(例えば、クロロフィル、β−カロチン等)等が挙げられる。
Examples of the powder component include inorganic powders (for example, talc, kaolin, mica, silk mica (serisite), white mica, gold mica, synthetic mica, red mica, black mica, permiculite, magnesium carbonate, calcium carbonate, silicic acid. Aluminum, barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungate, magnesium, silica, zeolite, barium sulfate, calcined calcium sulfate (baked sekko), calcium phosphate, fluoroapatite, hydroxyapatite, ceramic powder , Metal soaps (eg zinc myristate, calcium palmitate, aluminum stearate), boron nitride, etc.; Organic powders (eg polyamide resin powder (nylon powder), polyethylene powder, polymethyl methacrylate powder, polystyrene powder, styrene And acrylic acid copolymer resin powder, benzoguanamine resin powder, polytetrafluorinated ethylene powder, cellulose powder, etc.; inorganic white pigments (eg, titanium dioxide, zinc oxide, etc.); inorganic red pigments (eg, iron oxide (eg, iron oxide) Bengala), iron titanate, etc.); Inorganic brown pigments (eg, γ-iron oxide, etc.); Inorganic yellow pigments (eg, yellow iron oxide, ocher, etc.); Inorganic black pigments (eg, black iron oxide, low) (Titanium oxide, etc.); Inorganic purple pigments (eg, mango violet, cobalt violet, etc.); Inorganic green pigments (eg, chromium oxide, chromium hydroxide, cobalt titanate, etc.); Inorganic blue pigments (eg, ultramarine, etc.) Navy blue, etc.); Pearl pigments (eg, titanium oxide coated mica, titanium oxide coated bismuth oxychloride, titanium oxide coated talc, colored titanium oxide coated mica, bismuth oxychloride, fish scale foil, etc.); Metal powder pigments (eg, aluminum powder, Copper powder, etc.); Organic pigments such as zirconium, barium or aluminum lake (eg, Red 201, Red 202, Red 204, Red 205, Red 220, Red 226, Red 228, Red 405, Organic pigments such as Orange 203, Orange 204, Yellow 205, Yellow 401, and Blue 404, Red 3, Red 104, Red 106, Red 227, Red 230, Red 401, Red 505, orange 205, yellow 4, yellow 5, yellow 202, yellow 203, green 3, blue 1, etc.); natural pigments (eg, chlorophyll, β-carotene, etc.) and the like.
金属イオン封鎖剤としては、例えば、1−ヒドロキシエタン−1,1−ジフォスホン酸、1−ヒドロキシエタン−1,1− ジフォスホン酸四ナトリウム塩、エデト酸二ナトリ
ウム、エデト酸三ナトリウム、エデト酸四ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリウム、メタリン酸ナトリウム、グルコン酸、リン酸、クエン酸、アスコルビン酸、コハク酸、エデト酸、エチレンジアミンヒドロキシエチル三酢酸3ナトリウム等が挙げられる。
Examples of the metal ion sequestering agent include 1-hydroxyethane-1,1-diphosphonic acid, 1-hydroxyethane-1,1-diphosphonic acid tetrasodium salt, disodium edetate, trisodium edetate, and tetrasodium edetate. , Sodium citrate, sodium polyphosphate, sodium metaphosphate, gluconic acid, phosphoric acid, citric acid, ascorbic acid, succinic acid, edetic acid, trisodium ethylenediaminehydroxyethyl triacetate and the like.
低級アルコールとしては、例えば、エタノール、プロパノール、イソプロパノール、イソブチルアルコール、t−ブチルアルコール等が挙げられる。 Examples of the lower alcohol include ethanol, propanol, isopropanol, isobutyl alcohol, t-butyl alcohol and the like.
単糖としては、例えば、三炭糖(例えば、D−グリセリルアルデヒド、ジヒドロキシアセトン等);四炭糖(例えば、D−エリトロース、D−エリトルロース、D−トレオース、エリスリトール等);五炭糖(例えば、L−アラビノース、D−キシロース、L−リキソース、D−アラビノース、D−リボース、D−リブロース、D−キシルロース、L−キシルロース等);六炭糖(例えば、D−グルコース、D−タロース、D−ブシコース、D−ガラクトース、D−フルクトース、L−ガラクトース、L−マンノース、D−タガトース等);七炭糖(例えば、アルドヘプトース、ヘプロース等);八炭糖(例えば、オクツロース等);デオキシ糖(例えば、2−デオキシ−D−リボース、6−デオキシ−L−ガラクトース、6−デオキシ−L−マンノース等);アミノ糖(例えば、D−グルコサミン、D−ガラクトサミン、シアル酸、アミノウロン酸、ムラミン酸等);ウロン酸(例えば、D−グルクロン酸、D−マンヌロン酸、L−グルロン酸、D−ガラクツロン酸、L−イズロン酸等)等が挙げられる。 Examples of the simple sugar include tricarbose (eg, D-glycerylaldehyde, dihydroxyacetone, etc.); tetracarbose (eg, D-erythulose, D-elittlerose, D-treose, erythritol, etc.); , L-arabinose, D-xylulose, L-lyxose, D-arabinose, D-ribose, D-libulose, D-xylulose, L-xylulose, etc.; -Bushicose, D-galactose, D-fructose, L-galactose, L-mannose, D-tagatose, etc.); Seven-carbon sugar (eg, aldoheptose, heprose, etc.); Eight-carbon sugar (eg, octulose, etc.); For example, 2-deoxy-D-ribose, 6-deoxy-L-galactose, 6-deoxy-L-mannose, etc.; amino sugars (eg, D-glucosamine, D-galactosamine, sialic acid, aminouronic acid, muramic acid, etc.) ); Uronic acid (for example, D-glucuronic acid, D-mannuronic acid, L-glulonic acid, D-galacturonic acid, L-isulonic acid, etc.) and the like.
オリゴ糖としては、例えば、ショ糖、グンチアノース、ウンベリフェロース、ラクトース、プランテオース、イソリクノース類、α,α−トレハロース、ラフィノース、リクノース類、ウンビリシン、スタキオースベルバスコース類等が挙げられる。
多糖としては、例えば、セルロース、クインスシード、コンドロイチン硫酸、デンプン、ガラクタン、デルマタン硫酸、グリコーゲン、アラビアガム、ヘパラン硫酸、ヒアルロン酸、トラガントガム、ケラタン硫酸、コンドロイチン、キサンタンガム、ムコイチン硫酸、グアガム、デキストラン、ケラト硫酸、ローカストビーンガム、サクシノグルカン、カロニン酸等が挙げられる。
Examples of oligosaccharides include sucrose, gunthianose, umbelliferose, lactose, planteos, isolikunoses, α, α-trehalose, raffinose, lycnoses, umbilicin, stachyose velvas and the like.
Examples of polysaccharides include cellulose, quince seed, chondroitin sulfate, starch, galactan, dermatan sulfate, glycogen, Arabic gum, heparan sulfate, hyaluronic acid, tragant gum, keratane sulfate, chondroitin, xanthan gum, mucoitin sulfate, guagam, dextran, and keratosulfate. , Locust bean gum, succinoglucan, caronic acid and the like.
アミノ酸としては、例えば、中性アミノ酸(例えば、スレオニン、システイン等);塩基性アミノ酸(例えば、ヒドロキシリジン等)等が挙げられる。また、アミノ酸誘導体として、例えば、アシルサルコシンナトリウム(ラウロイルサルコシンナトリウム) 、アシ
ルグルタミン酸塩、アシルβ−アラニンナトリウム、グルタチオン、ピロリドンカルボン酸等が挙げられる。
Examples of amino acids include neutral amino acids (eg, threonine, cysteine, etc.); basic amino acids (eg, hydroxylysine, etc.) and the like. Examples of the amino acid derivative include acyl sarcosine sodium (lauroyl sarcosine sodium), acyl glutamate, acyl β-alanine sodium, glutathione, pyrrolidone carboxylic acid and the like.
有機アミンとしては、例えば、モノエタノールアミン、ジエタノールアミン、トリエタノールアミン、モルホリン、トリイソプロパノールアミン、2−アミノ−2−メチル−1,3−プロパンジオール、2−アミノ−2−メチル−1−プロパノール等が挙げられる。 Examples of the organic amine include monoethanolamine, diethanolamine, triethanolamine, morpholine, triisopropanolamine, 2-amino-2-methyl-1,3-propanediol, 2-amino-2-methyl-1-propanol and the like. Can be mentioned.
高分子エマルジョンとしては、例えば、アクリル樹脂エマルジョン、ポリアクリル酸エチルエマルジョン、アクリルレジン液、ポリアクリルアルキルエステルエマルジョン、ポリ酢酸ビニル樹脂エマルジョン、天然ゴムラテックス等が挙げられる。 Examples of the polymer emulsion include an acrylic resin emulsion, an ethyl polyacrylate emulsion, an acrylic resin liquid, a polyacrylic alkyl ester emulsion, a polyvinyl acetate resin emulsion, and a natural rubber latex.
pH調整剤としては、例えば、乳酸−乳酸ナトリウム、クエン酸−クエン酸ナトリウム、コハク酸−コハク酸ナトリウム等の緩衝剤等が挙げられる。
ビタミン類としては、例えば、ビタミンA、B1、B2、B6、C、E及びその誘導体
、パントテン酸及びその誘導体、ビオチン等が挙げられる。
Examples of the pH adjuster include buffers such as lactic acid-sodium lactate, citric acid-sodium citrate, and succinic acid-sodium succinate.
Examples of vitamins include vitamins A, B1, B2, B6, C, E and their derivatives, pantothenic acid and its derivatives, biotin and the like.
酸化防止剤としては、例えば、トコフェロール類、ジブチルヒドロキシトルエン、ブチルヒドロキシアニソール、没食子酸エステル類等が挙げられる。
酸化防止助剤としては、例えば、リン酸、クエン酸、アスコルビン酸、マレイン酸、マロン酸、コハク酸、フマル酸、ケファリン、ヘキサメタフォスフェイト、フィチン酸、エチレンジアミン四酢酸等が挙げられる。
Examples of the antioxidant include tocopherols, dibutylhydroxytoluene, butylhydroxyanisole, gallic acid esters and the like.
Examples of the antioxidant aid include phosphoric acid, citric acid, ascorbic acid, maleic acid, malonic acid, succinic acid, fumaric acid, kephalin, hexametaphosphate, phytic acid, ethylenediaminetetraacetic acid and the like.
有機変性粘土鉱物は、例えば、スメクタイト系(ヘクトライト、ベントナイト、モンモリロナイト等)、カオリナイト、イライト、マリーン粘土鉱物(海泥)、デザートローズ粘土鉱物、パスカライト等の粘土鉱物を、4級アミン基やカルボキシル基等によって変性したものが挙げられる。市販されているものとしては、「ベントン38V(ジメチルジステアリルアンモニウム変性ヘクトライト)」(エレメンティス社製)等を例示できる。これらは一般に、水中油乳化剤型の安定化剤として用いられる。 Organically modified clay minerals include, for example, smectite-based (hectorite, bentonite, montmorillonite, etc.), kaolinite, illite, marine clay mineral (sea mud), desert rose clay mineral, pascalite, and other clay minerals, as well as quaternary amine groups. Examples thereof include those modified by a carboxyl group or the like. Examples of commercially available products include "Benton 38V (dimethyl distearyl ammonium-modified hectorite)" (manufactured by Elementis). These are generally used as oil emulsifier type stabilizers in water.
本発明の肌状態改善用化粧料基剤は、通常の水中油乳化の手順により調製することができる。 The cosmetic base for improving skin condition of the present invention can be prepared by a usual procedure of oil emulsification in water.
本発明の化粧料基剤は、皮膚において角層細胞が隙間なく接着してつまった状態(コンパクト角層)を改善し、角層細胞間に間隙があるかご状態を呈するバスケットウィーブ角層形成を促進する。後述の実施例で示されるように、バスケットウィーブ角層が形成された皮膚では角層水分量が増加し、皮膚柔軟性が向上し、肌色が改善し、成分貯留性・浸透性が向上し、キメが改善する等、肌状態が改善されるため、本発明の化粧料基剤は肌状態改善用途に好適である。肌状態が改善する事により、肌の老化を抑制したり、化粧のノリが良好になったり、肌の見た目が美しい印象を与えたりできる。なお、肌色の改善とは、ソフトフォーカス効果(ぼかし効果)により肌の色や質感が好印象になることや、肌色が明るくなる(明度が上がる)ことを指す。また、キメとは、皮膚表面の形態を指し、皮溝(皮膚表面を縦横・放射状に走る細かく浅い溝)や皮丘(皮溝で囲まれた微小の隆起)からなる皮膚紋理の細かさ/粗さ、整/歪により、良し悪しが評価される。 The cosmetic base of the present invention improves the state in which the stratum corneum cells adhere tightly to each other in the skin (compact stratum corneum), and forms a basket weave stratum corneum showing a cage state in which there are gaps between the stratum corneum cells. Facilitate. As shown in Examples described later, in the skin on which the basket weave stratum corneum is formed, the water content of the stratum corneum increases, the skin flexibility is improved, the skin color is improved, and the component retention and permeability are improved. Since the skin condition is improved such as the texture is improved, the cosmetic base of the present invention is suitable for the skin condition improving application. By improving the skin condition, it is possible to suppress the aging of the skin, improve the make-up paste, and give the impression that the skin looks beautiful. The improvement of skin color means that the soft focus effect (blurring effect) gives a good impression of the skin color and texture, and that the skin color becomes brighter (brightness increases). The texture refers to the morphology of the skin surface, and is the fineness of the skin pattern consisting of skin grooves (fine and shallow grooves that run vertically, horizontally and radially on the skin surface) and skin hills (small ridges surrounded by skin grooves). Good or bad is evaluated by roughness and adjustment / distortion.
本発明の肌状態改善用化粧料基剤は、肌状態改善成分として化粧料に好適に配合することができる。この際、他の任意成分を共に化粧料に配合することができる。
かかる化粧料の製造においては、本発明の肌状態改善用化粧料基剤に他の任意成分を添加してもよいし、本発明の肌状態改善用化粧料基剤を乳化調製する際に共に混合してもよい。
他の任意成分としては、例えば、;消炎剤(例えば、グリチルリチン酸誘導体、グリチルレチン酸誘導体、サリチル酸誘導体、ヒノキチオール、酸化亜鉛、アラントイン等);美白剤(例えば、胎盤抽出物、ユキノシタ抽出物、アルブチン等);各種抽出物(例えば、オウバク、オウレン、シコン、シャクヤク、センブリ、バーチ、セージ、ビワ、ニンジン、アロエ、ゼニアオイ、アイリス、ブドウ、ヨクイニン、ヘチマ、ユリ、サフラン、センキュウ、ショウキュウ、オトギリソウ、オノニス、ニンニク、トウガラシ、チンピ、トウキ、海藻等)、賦活剤(例えば、ローヤルゼリー、感光素、コレステロール誘導体等);血行促進剤(例えば、ノニル酸ワレニルアミド、ニコチン酸ベンジルエステル、ニコチン酸β−ブトキシエチルエステル、カプサイシン、ジンゲロン、カンタリスチンキ、イクタモール、タンニン酸、α−ボルネオール、ニコチン酸トコフェロール、イノシトールヘキサニコチネート、シクランデレート、シンナリジン、トラゾリン、アセチルコリン、ベラパミル、セファランチン、γ−オリザノール等);抗脂漏剤(例えば、硫黄、チアントール等);抗炎症剤(例えば、トラネキサム酸、チオタウリン、ヒポタウリン等)等が挙げられる。
The skin condition improving cosmetic base of the present invention can be suitably blended in cosmetics as a skin condition improving ingredient. At this time, other optional ingredients can be added to the cosmetics together.
In the production of such cosmetics, other optional ingredients may be added to the skin condition improving cosmetic base of the present invention, or both when emulsifying and preparing the skin condition improving cosmetic base of the present invention. It may be mixed.
Other optional components include, for example; anti-inflammatory agents (eg, glycyrrhizinic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokithiol, zinc oxide, allantin, etc.); whitening agents (eg, placenta extract, yukinoshita extract, arbutin, etc.) ); Various extracts (eg, Oubaku, Ouren, Shikon, Shakuyaku, Senburi, Birch, Sage, Biwa, Carrot, Aloe, Zeniaoi, Iris, Grape, Yokuinin, Hechima, Yuri, Saffron, Senkyu, Shokyu, Otogirisou, Ononis , Carrots, peppers, tinctures, tinctures, seaweeds, etc.), activators (eg, royal jelly, photosensitizers, cholesterol derivatives, etc.); blood circulation promoters (eg, nonylate valenylamide, nicotinic acid benzyl ester, nicotinic acid β-butoxyethyl ester) , Capsaicin, Zingeron, Cantaristinki, Ictamoll, Tannic acid, α-Bornooleol, Tocopherol nicotinate, Inositol hexanicotinate, Cyclanderate, Cinnaridine, Trazoline, Acetylcholine, Verapamil, Cepharantin, γ-Oryzanol, etc.); Agents (eg, sulfur, thiantoll, etc.); Anti-inflammatory agents (eg, tranexamic acid, thiotaurine, hypotaurine, etc.) and the like.
<本発明のスクリーニング方法>
本発明のスクリーニング方法は、培養皮膚におけるバスケットウィーブ(Basket
weave)角層形成を指標とする、肌状態改善用化粧料基剤のスクリーニング方法で
ある。
本スクリーニング方法は、培養皮膚を使用してin vitroで行うため、被験者か
ら皮膚試料を採取することなく、非侵襲的にスクリーニングを行うことができる。
なお、スクリーニングに使用する培養皮膚は、生体から採取した皮膚を培養したものでもよいし、三次元培養皮膚モデルとして培養・構築したものでもよい。
生体から採取し培養した培養皮膚を用いる場合は、角層が未成熟な状態のものが好ましい。
三次元培養皮膚モデルは、表皮基本構造の基底層から顆粒層、有棘層、及び角層を有する、正常ヒト表皮角化細胞から培養・構築したものを好ましく用いることができ、例えば市販のEPI-200キット(Mattek社)等を使用できる。
角層が未成熟な培養皮膚や、三次元培養皮膚モデルは、正常な皮膚とは異なり、バスケットウィーブ角層ではなくコンパクト角層を有しているが、肌状態改善作用を有する化粧料基剤を適用することによりバスケットウィーブ角層形成が促進されること、及びバスケットウィーブ角層形成と肌状態とに相関関係があることに基づき、該形成をスクリーニングの指標とすることができる。
なお、ここでいう肌状態改善とは、角層水分量増加、皮膚柔軟性向上、肌色改善、成分貯留・浸透性向上、及び/又はキメ改善をさす。
<Screening method of the present invention>
The screening method of the present invention is a basket weave in cultured skin.
Weave) This is a screening method for a cosmetic base for improving skin condition, using the formation of the stratum corneum as an index.
Since this screening method is performed in vitro using cultured skin, screening can be performed non-invasively without collecting a skin sample from the subject.
The cultured skin used for screening may be one obtained by culturing skin collected from a living body, or one cultivated and constructed as a three-dimensional cultured skin model.
When using cultured skin collected from a living body and cultured, it is preferable that the stratum corneum is in an immature state.
As the three-dimensional cultured skin model, those cultured and constructed from normal human epidermal keratinocytes having a stratum granulosum, a stratum spinosum, and a stratum spinosum from the basal layer of the basic epidermal structure can be preferably used, for example, a commercially available EPI. -200 kits (Mattek) etc. can be used.
Unlike normal skin, cultured skin with immature stratum corneum and three-dimensional cultured skin model have a compact stratum corneum instead of basket weave stratum corneum, but a cosmetic base having a skin condition improving effect. Based on the fact that basket weave stratum corneum formation is promoted by applying the above and that there is a correlation between basket weave stratum corneum formation and skin condition, the formation can be used as an index for screening.
The term "improvement of skin condition" as used herein refers to an increase in the amount of water in the stratum corneum, an improvement in skin flexibility, an improvement in skin color, an improvement in component retention / permeability, and / or an improvement in texture.
具体的なスクリーニング手順の一例としては、定法に従って前培養した培養皮膚に対して、被験試料を添加し、さらに室温にて4〜48時間培養した後に、培養皮膚におけるバスケットウィーブ角層形成を評価する。 As an example of a specific screening procedure, a test sample is added to cultured skin precultured according to a conventional method, and after further culturing at room temperature for 4 to 48 hours, basket weave stratum corneum formation in the cultured skin is evaluated. ..
バスケットウィーブ角層形成の評価は、培養皮膚の断面を観察することにより行うことができる。例えば、培養終了後の培養皮膚の切片を常法により作製して、ヘマトキシリンエオジン(HE)染色等を施した後にして光学顕微鏡等で観察すればよい。
この場合、パラフィン包埋から作製した切片において、角層最上部から最下部までの距離(角層距離)が、無処置の場合の角層距離に対して好ましくは110%以上、より好ましくは120%以上である場合に、該被験試料はバスケットウィーブ角層形成を促進すると判断することができる。あるいは、HE染色画像の角層部分のみの観察画像を切り出して、二値化処理後、全ピクセル数に対する白ピクセル(角層細胞間の間隙に対応)数の割合を算出するなどして、角層全体における間隙の割合を算出し、該割合が好ましくは15%以上、より好ましくは25%以上、さらに好ましくは40%以上の場合に、該被験試料はバスケットウィーブ角層形成を促進すると判断することができる。
Evaluation of basket weave stratum corneum formation can be performed by observing the cross section of the cultured skin. For example, a section of the cultured skin after completion of the culture may be prepared by a conventional method, stained with hematoxylin eosin (HE) or the like, and then observed with an optical microscope or the like.
In this case, in the section prepared from paraffin embedding, the distance from the top to the bottom of the stratum corneum (corneal layer distance) is preferably 110% or more, more preferably 120, with respect to the stratum corneum distance in the case of no treatment. When it is% or more, it can be judged that the test sample promotes basket weave stratum corneum formation. Alternatively, the observation image of only the stratum corneum portion of the HE-stained image is cut out, and after binarization processing, the ratio of the number of white pixels (corresponding to the gap between the stratum corneum cells) to the total number of pixels is calculated to calculate the angle. The ratio of the gap in the entire layer is calculated, and when the ratio is preferably 15% or more, more preferably 25% or more, still more preferably 40% or more, it is determined that the test sample promotes basket weave stratum corneum formation. be able to.
また、培養皮膚の角層蛋白質を検出することによっても、バスケットウィーブ角層形成を評価することもできる。例えば、培養終了後の培養皮膚の表面に対してテープストリッピングを行って採取した角層試料から角層蛋白質を検出すればよく、より好ましくはその分布を画像で取得する。角層蛋白質としては、細胞接着蛋白質、角層間物質、角層細胞構成成分等が挙げられ、好ましくは角層細胞接着因子(コルネオデスモゾーム)であり、より好ましくはその構成蛋白質であるデスモグレインである。
検出方法は、例えば特開2007−199053号公報に記載された、角層蛋白質の免疫染色による方法が好ましい。
この場合、例えば蛍光検出された角層蛋白質の分布が、角層細胞の全面であるか、角層細胞の辺縁部に偏在しているかを観察し、辺縁部に偏在している場合に、該被験試料はバスケットウィーブ角層形成を促進すると判断することができる。あるいは、デスモグレイン等の角層蛋白質が分解の進行により減少している場合、例えば特開2007−199053号公報のように、蛍光検出された角層蛋白質の角層細胞1個当たりのピクセル数をカウントし、無処置の場合に対して好ましくは90%以下、より好ましくは80%以下であ
る場合に、該被験試料はバスケットウィーブ角層形成を促進すると判断することができる。
It is also possible to evaluate basket weave stratum corneum formation by detecting stratum corneum proteins in cultured skin. For example, the stratum corneum protein may be detected from the stratum corneum sample collected by performing tape stripping on the surface of the cultured skin after the completion of the culture, and more preferably, the distribution thereof is acquired by an image. Examples of the stratum corneum protein include cell adhesion proteins, stratum corneum substances, stratum corneum cell constituents, etc., preferably a stratum corneum cell adhesion factor (corneodesmosome), and more preferably desmoglein, which is a constituent protein thereof. ..
As the detection method, for example, the method described in JP-A-2007-199053 by immunostaining of stratum corneum protein is preferable.
In this case, for example, it is observed whether the distribution of the fluorescently detected stratum corneum protein is unevenly distributed on the entire surface of the stratum corneum cells or on the marginal portion of the stratum corneum cells, and when it is unevenly distributed on the marginal portion. , The test sample can be determined to promote basket weave stratum corneum formation. Alternatively, when a stratum corneum protein such as desmoglein is reduced due to the progress of degradation, for example, as in JP-A-2007-199053, the number of pixels of the stratum corneum protein detected by fluorescence per stratum corneum cell is determined. When counted, preferably 90% or less, more preferably 80% or less of the untreated case, it can be determined that the test sample promotes basket weave stratum corneum formation.
以下、本発明を実施例により更に詳細に説明するが、本発明は、その要旨を超えない限り、以下の実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to the following Examples as long as the gist thereof is not exceeded.
<製造例>
表1に示す処方に従って、水中油乳化剤型の実施例1〜4の組成物を製造した。すなわち、A成分、B成分、及びC成分をそれぞれ加熱溶解後、C成分にA成分、続いてB成分を撹拌しながら徐々に加えて乳化して、水中油乳化組成物を得た。なお、多価アルコールの含有量が、実施例1は10.0%であるのに対し、実施例2〜4は18.0%である。また、油剤の種類について、実施例1〜3は極性油であるメドフォームの種子油を含有するが、実施例4はこれを非極性油であるスクワランへ変更した。
表2に示す処方に従って、油中水乳化剤型の比較例1の組成物を製造した。すなわち、D成分及びE成分をそれぞれ加熱溶解した後、D成分にE成分を撹拌しながら徐々に加えて乳化して、油中水乳化組成物を得た。
また、比較例2としてワセリン(大洋製薬株式会社製)を用意した。
<Manufacturing example>
The oil-in-water emulsifier-type compositions of Examples 1 to 4 were produced according to the formulations shown in Table 1. That is, after each of the A component, the B component, and the C component was heated and dissolved, the A component and then the B component were gradually added to the C component with stirring and emulsified to obtain an oil-in-water emulsified composition. The content of the polyhydric alcohol is 10.0% in Example 1 and 18.0% in Examples 2 to 4. Regarding the type of oil, Examples 1 to 3 contained seed oil of Medfoam, which is a polar oil, but Example 4 changed this to squalane, which is a non-polar oil.
A water-in-oil emulsifier type composition of Comparative Example 1 was produced according to the formulation shown in Table 2. That is, after each of the D component and the E component was heated and dissolved, the E component was gradually added to the D component with stirring and emulsified to obtain a water emulsified composition in oil.
In addition, Vaseline (manufactured by Taiyo Pharmaceutical Co., Ltd.) was prepared as Comparative Example 2.
<試験例1>三次元培養皮膚モデルを用いたin vitroスクリーニング
市販の三次元培養皮膚モデル(EPI-200キット、Mattek社)を用いて試験を行った。キ
ットの使用方法に従って皮膚モデルを培養し、皮膚モデルの各カップ内(角層上)に、被験物質として実施例1〜5及び比較例1〜2の組成物を100μLずつ添加し、室温にて4〜48時間培養した。培養終了後、培養皮膚モデルをPBS(−)で洗浄し、10%中性緩衝ホルマリン液にて固定、パラフィン包埋し、常法通りに組織切片を作製した。また、対照として無処置の皮膚モデルについても、同様に培養し、組織切片を作製した。作製した各組織切片についてヘマトキシリンエオジン(HE)染色を施し、光学顕微鏡観察により、角層表皮の組織構造を観察した(図1)。染色角層の撮像を用いて角層距離を測定し、無処置の角層に対する割合を算出した(表3)。また、二値化処理した角層部分の画像において、全ピクセル数に対する白ピクセル数の割合を算出して、角層全体に対する間隙の割合とした(表3)。
<Test Example 1> In vitro screening using a 3D cultured skin model A test was conducted using a commercially available 3D cultured skin model (EPI-200 kit, Mattek). The skin model is cultured according to the method of using the kit, and 100 μL of the compositions of Examples 1 to 5 and Comparative Examples 1 and 2 are added as test substances in each cup (on the stratum corneum) of the skin model at room temperature. The cells were cultured for 4 to 48 hours. After completion of the culture, the cultured skin model was washed with PBS (-), fixed with a 10% neutral buffered formalin solution, embedded in paraffin, and tissue sections were prepared as usual. In addition, as a control, an untreated skin model was also cultured in the same manner to prepare tissue sections. Each tissue section prepared was stained with hematoxylin eosin (HE), and the tissue structure of the stratum corneum was observed by optical microscope observation (Fig. 1). The stratum corneum distance was measured using imaging of the stained stratum corneum, and the ratio to the untreated stratum corneum was calculated (Table 3). Further, in the image of the binarized stratum corneum portion, the ratio of the number of white pixels to the total number of pixels was calculated and used as the ratio of the gap to the entire stratum corneum (Table 3).
図1、表3に示すように、無処置の皮膚モデル(対照)では角層細胞が隙間なく接着しているのに対し、実施例1〜4の水中油乳化剤型の組成物を添加した皮膚モデルでは、角層細胞間の間隙が形成されて角層距離が大きくなり、バスケットウィーブ角層の形成が促進されていることが確認された。特に、多価アルコールを18.0質量%含有する実施例2〜4の方が、10質量%含有する実施例1よりも角層における間隙の割合が大きく、バスケットウィーブ角層の形成は進んでいた。比較例1の油中水乳化剤型の組成物及び比較例2のワセリンを添加した皮膚モデルでは、いずれも無処置の対照皮膚モデルと同様にバスケットウィーブ角層の形成は認められなかった。
これらの結果より、水中油乳化剤型の基剤がバスケットウィーブ角層の形成に有効であり、特定量の多価アルコールを含有することがより好ましいことが示された。
As shown in FIGS. 1 and 3, in the untreated skin model (control), the stratum corneum cells adhered without gaps, whereas the skin to which the oil-in-water emulsifier-type composition of Examples 1 to 4 was added was added. In the model, it was confirmed that the gap between the stratum corneum cells was formed and the distance between the stratum corneum was increased, and the formation of the basket weave stratum corneum was promoted. In particular, Examples 2 to 4 containing 18.0% by mass of the polyhydric alcohol had a larger proportion of gaps in the stratum corneum than Example 1 containing 10% by mass, and the formation of the basket weave stratum corneum proceeded. There was. In the skin model to which the water-in-oil emulsifier type composition of Comparative Example 1 and Vaseline of Comparative Example 2 were added, the formation of the basket weave stratum corneum was not observed as in the untreated control skin model.
From these results, it was shown that the oil-in-water emulsifier-type base is effective in forming the basket weave stratum corneum, and it is more preferable to contain a specific amount of polyhydric alcohol.
<試験例2>水中油乳化剤型の基剤のヒトに対する連用試験
実施例3の水中油エマルション処方を30〜40代の女性被験者22名に、1日2回、1か月間連続して使用してもらった。連用前及び1ヵ月連用後に、Skicon−200により角層水分量を、ヴィーナストロンを用いて往路2g荷重時の周波数変化(Δf)を指標に角層柔軟性を、それぞれ測定した。また、ビデオマイクロスコープを用いて皮膚表面のキメの状態(皮溝の鮮明度及び皮丘の形)を観察し、熟練者が5段階スコア(悪化、やや悪化、変化なし、やや改善、改善)で評価した。また、同被験者からテープストリッピング採取した角層細胞のデスモグレイン1の免疫染色を行い、その存在状態を指標に、バスケットウィーブ角層の形成状態を調べた。
<Test Example 2> Continuous use test of an oil-in-water emulsifier-type base for humans The oil-in-water emulsion formulation of Example 3 was used twice a day for 22 female subjects in their 30s and 40s for one month continuously. I got it. Before continuous use and after continuous use for 1 month, the water content of the stratum corneum was measured by Skion-200, and the flexibility of the stratum corneum was measured by using Venustron using the frequency change (Δf) under a load of 2 g on the outward path as an index. In addition, the texture of the skin surface (sharpness of the skin groove and the shape of the skin hill) was observed using a video microscope, and the expert scored 5 levels (deterioration, slightly worse, no change, slightly improved, improved). Evaluated in. In addition, immunostaining of desmoglein 1 in the stratum corneum cells collected by tape stripping from the same subject was performed, and the state of formation of the basket weave stratum corneum was examined using the presence status as an index.
なお、デスモグレイン1の免疫染色は、特開2007−199053号公報及びY. Naoe et al. Journal of Dermatological Science 57 (2010) 192-198を参考にした。
具体的には、市販の粘着テープを用い、被験者の頬部の角層細胞をテープを用い剥離、採取し、当該テープをスライドガラスに貼付し、キシレン中で半日処理して粘着テープを除去した。スライドガラスに付着した角層細胞に対し、デスモグレイン1の免疫染色を行った。当該免疫染色は、一次抗体としてAnti-Desmogrein 1, Mouse-Mono [Dsg1-P23](Progen 65110)を用い、二次抗体としてAlexa Fluor 488 Goat Anti-mouse IgG(Invitrogen A-11001)を用いて行い、染色された角層標本を共焦点レーザー顕微鏡にて観察した。
For immunostaining of desmoglein 1, Japanese Patent Application Laid-Open No. 2007-199053 and Y. Naoe et al. Journal of Dermatological Science 57 (2010) 192-198 were referred to.
Specifically, using a commercially available adhesive tape, the stratum corneum cells on the cheek of the subject were peeled off and collected using the tape, the tape was attached to a slide glass, and the adhesive tape was removed by treating with xylene for half a day. .. Desmoglein 1 immunostaining was performed on the stratum corneum cells attached to the slide glass. The immunostaining was performed using Anti-Desmogrein 1, Mouse-Mono [Dsg1-P23] (Progen 65110) as the primary antibody and Alexa Fluor 488 Goat Anti-mouse IgG (Invitrogen A-11001) as the secondary antibody. The stained stratum corneum specimen was observed with a confocal laser scanning microscope.
図2に角層水分量の結果(全被験者の平均)を示す。実施例3の水中油乳化剤型の組成物の1ヵ月連用により、角層水分量が上昇したことが分かる。
図3に角層柔軟性の結果を示す(全被験者の平均)。縦軸の周波数変化Δf[Hz]の絶対値が大きいほど柔軟性が高いことを表すことから、実施例3の水中油乳化剤型の組成物の1ヵ月連用により、角層柔軟性が向上したことが分かる。
図4に一被験者の皮膚表面の撮像を示す。また、5段階スコアによるキメの状態評価の結果を表4に示す。実施例3の水中油乳化剤型の組成物の1ヵ月連用により、キメの状態(皮溝の鮮明度及び皮丘の形)に改善が認められたことが分かる。
FIG. 2 shows the results of the water content of the stratum corneum (average of all subjects). It can be seen that the water content of the stratum corneum increased by the continuous use of the oil-in-water emulsifier type composition of Example 3 for one month.
FIG. 3 shows the results of stratum corneum flexibility (average of all subjects). Since the larger the absolute value of the frequency change Δf [Hz] on the vertical axis, the higher the flexibility, the flexibility of the stratum corneum was improved by the continuous use of the oil-in-water emulsifier type composition of Example 3 for one month. I understand.
FIG. 4 shows an image of the skin surface of one subject. Table 4 shows the results of texture condition evaluation using a 5-point score. It can be seen that the texture condition (sharpness of the skin groove and the shape of the skin hill) was improved by continuous use of the oil-in-water emulsifier type composition of Example 3 for one month.
図5に一被験者のデスモグレイン1の免疫染色した角層細胞の撮像を示す。また、特開2007−199053号公報を参照して、蛍光検出されたデスモグレイン1の角層細胞1個あたりのピクセル数をカウントした結果を図6に示す(全被験者の平均)。実施例3の水中油乳化剤型の組成物の1ヵ月連用前には細胞全面に存在していたデスモグレイン1は、1ヵ月連用後には、分解が進んで細胞辺縁部のみに残存している様子が観察され、連用前と比較して連用後では、角層細胞1個あたりのデスモグレイン1発現量が有意に減少していることが確認された。実施例3の水中油乳化剤型の組成物の1ヵ月連用により、バスケットウィーブ角層の形成が促進されたと考えられる。 FIG. 5 shows an imaging of immunostained stratum corneum cells of one subject, desmoglein 1. Further, with reference to Japanese Patent Application Laid-Open No. 2007-199053, the result of counting the number of pixels per fluorescently detected desmoglein 1 per stratum corneum cell is shown in FIG. 6 (average of all subjects). Desmoglein 1, which was present on the entire cell surface before the one-month continuous use of the oil-in-water emulsifier-type composition of Example 3, was decomposed and remained only at the cell margin after the one-month continuous use. The situation was observed, and it was confirmed that the expression level of desmoglein 1 per stratum corneum cell was significantly reduced after continuous use as compared with before continuous use. It is considered that the formation of the basket weave stratum corneum was promoted by the continuous use of the oil-in-water emulsifier type composition of Example 3 for one month.
<試験例3>バスケットウィーブ角層の光拡散性の検討
試験例1と同様に三次元皮膚モデルを培養し、皮膚モデルの各カップ内(角層上)に、実施例3の組成物を100μLずつ添加し、室温にて24時間培養して、バスケットウィーブ角層を形成させた。比較として組成物を未添加のものも用意し、未成熟な角層(コン
パクト角層)とした。
作製後の試料に対して、ヘイズメーターNDH5000(日本電色工業社製)を用いて、全光線透過率、拡散透過率、及び平行透過率を測定し、ヘイズ(Haze(%)=拡散透過率/全光透過率×100%)を算出した。結果を図7(a)に示す。
また、作製後の試料において、光学顕微鏡(明視野)により、透過拡散光を直接撮影した。結果を図7(b)に示す。
<Test Example 3> Examination of light diffusivity of basket weave stratum corneum A three-dimensional skin model is cultured in the same manner as in Test Example 1, and 100 μL of the composition of Example 3 is placed in each cup (on the stratum corneum) of the skin model. They were added one by one and cultured at room temperature for 24 hours to form a basket weave stratum corneum. For comparison, an unadded composition was also prepared to prepare an immature stratum corneum (compact stratum corneum).
The haze meter NDH5000 (manufactured by Nippon Denshoku Kogyo Co., Ltd.) was used to measure the total light transmittance, diffusion transmittance, and parallel transmittance of the prepared sample, and haze (Haze (%) = diffusion transmittance). / Total light transmittance x 100%) was calculated. The results are shown in FIG. 7 (a).
In addition, the transmitted diffused light was directly photographed with an optical microscope (bright field) in the prepared sample. The results are shown in FIG. 7 (b).
バスケットウィーブ角層を形成した三次元培養皮膚モデルは、コンパクト角層の三次元培養皮膚モデルと比較して有意に高いヘイズを示し、光拡散性に優れることが示された(図7(a))。また、透過拡散光の撮影像からも、バスケットウィーブ角層は、コンパクト角層と比較して、光拡散性に優れることがわかる(図7(b))。
これらの結果から、バスケットウィーブ角層の形成により肌の光拡散性が向上し、そのソフトフォーカス効果(ぼかし効果)によって肌の色や質感が改善される可能性が示された。
The three-dimensional cultured skin model in which the basket weave stratum corneum was formed showed significantly higher haze than the three-dimensional cultured skin model of the compact stratum corneum, and was shown to be excellent in light diffusivity (FIG. 7 (a)). ). Further, it can be seen from the photographed image of the transmitted diffused light that the basket weave stratum corneum is superior in light diffusing property as compared with the compact stratum corneum (FIG. 7 (b)).
From these results, it was shown that the formation of the basket weave stratum corneum improves the light diffusivity of the skin, and the soft focus effect (blurring effect) may improve the color and texture of the skin.
<試験例4>バスケットウィーブ角層と肌色の明るさとの相関の検討
50代〜60代の女性被験者41名に対して、分光測色器によりL*値を測定した。
同被験者からテープストリッピングにより角層細胞を採取し、試験例2と同様に該角層細胞のデスモグレイン1の免疫染色を行った。取得した免疫染色像のうち、角層細胞が存在しない箇所を削除した残余の全ピクセル数に対して、デスモグレイン1を示すピクセル数の割合を算出した。この値が小さいほど、コルネオデスモゾームの分解が進行していること、すなわちバスケットウィーブ角層形成度合いが高いことを示す。
解析ソフト(JMP ver.10.0(SAS社製))を使用して、L*値と前記割合との相関分析を行った。
<Test Example 4> Examination of correlation between basket weave stratum corneum and skin color brightness For 41 female subjects in their 50s to 60s, L * values were measured with a spectrophotometer.
Horn layer cells were collected from the same subject by tape stripping, and immunostaining of desmoglein 1 of the stratum corneum cells was performed in the same manner as in Test Example 2. From the obtained immunostained images, the ratio of the number of pixels showing desmoglein 1 was calculated with respect to the total number of pixels remaining after removing the portion where the stratum corneum cells did not exist. The smaller this value is, the more the decomposition of Corneodesmosome is progressing, that is, the higher the degree of basket weave stratum corneum formation.
Correlation analysis between the L * value and the above ratio was performed using analysis software (JMP ver. 10.0 (manufactured by SAS)).
結果を図8に示す。コルネオデスモゾームの分解が進み、バスケットウィーブ角層形成度合いが高いほど、L*値が大きく、肌色が明るいことが示された。この結果から、バスケットウィーブ角層の形成により、肌色の明るさが向上することが明らかとなった。 The results are shown in FIG. It was shown that the higher the degree of basket weave stratum corneum formation, the larger the L * value and the lighter the skin color, as the decomposition of Corneodesmosome progressed. From this result, it was clarified that the formation of the basket weave stratum corneum improves the brightness of the skin color.
<試験例5>バスケットウィーブ角層と角層柔軟性との相関の検討(1)
20代〜70代の女性被験者93名に対して、ヴィーナストロンにより往路2g荷重時の周波数変化(Δf)を指標に、角層柔軟性を測定した。
同被験者からテープストリッピングにより角層細胞を採取し、試験例2と同様に該角層細胞のデスモグレイン1の免疫染色を行った。デスモグレイン1の分解の程度を指標に、すなわち角層細胞に残存しているコルネオデスモゾームが辺縁部に偏在している度合いが高いかを観察して、各被験者を順位づけした。この順位が小さいほど、コルネオデスモゾームが辺縁部に偏在している度合いが高いこと、すなわちバスケットウィーブ角層形成度合いが高いことを示す。
解析ソフト(JMP ver.10.0(SAS社製))を使用して、周波数変化(Δf)値と前記順位との相関分析を行った。
<Test Example 5> Examination of correlation between basket weave stratum corneum and stratum corneum flexibility (1)
For 93 female subjects in their 20s to 70s, the flexibility of the stratum corneum was measured by Venustron using the frequency change (Δf) under a load of 2 g on the outward path as an index.
Horn layer cells were collected from the same subject by tape stripping, and immunostaining of desmoglein 1 of the stratum corneum cells was performed in the same manner as in Test Example 2. Each subject was ranked by observing whether the degree of degradation of desmoglein 1 was used as an index, that is, whether the corneodesmosome remaining in the stratum corneum cells was unevenly distributed in the marginal region. The smaller this rank is, the higher the degree of the Corneodesmosome is unevenly distributed in the marginal portion, that is, the higher the degree of basket weave stratum corneum formation.
Correlation analysis between the frequency change (Δf) value and the above rank was performed using analysis software (JMP ver. 10.0 (manufactured by SAS)).
結果を図9に示す。コルネオデスモゾームの分解が進み、バスケットウィーブ角層形成度合いが高いほど、周波数変化(Δf)値の絶対値が大きく、角層柔軟性が高いことが示された。この結果から、バスケットウィーブ角層の形成により、角層柔軟性が向上することが明らかとなった。 The results are shown in FIG. It was shown that the higher the degree of basket weave stratum corneum formation, the larger the absolute value of the frequency change (Δf) value, and the higher the stratum corneum flexibility, as the decomposition of the corneodesmosome progressed. From this result, it was clarified that the formation of the basket weave horny layer improves the horny layer flexibility.
<試験例6>バスケットウィーブ角層と角層柔軟性との相関の検討(2)
20代〜60代の女性被験者98名に対して、ヴィーナストロンにより往路2g荷重時の周波数変化(Δf)を指標に、角層柔軟性を測定した。
同被験者からテープストリッピングにより角層細胞を採取し、試験例2と同様に該角層
細胞のデスモグレイン1の免疫染色を行った。取得した免疫染色像から、試験例4と同様に全ピクセル数に対するデスモグレイン1を示すピクセル数の割合を算出した。
解析ソフト(JMP ver.10.0(SAS社製))を使用して、周波数変化(Δf)値と前記割合との相関分析を行った。
<Test Example 6> Examination of correlation between basket weave stratum corneum and stratum corneum flexibility (2)
For 98 female subjects in their 20s to 60s, the flexibility of the stratum corneum was measured by Venustron using the frequency change (Δf) under a 2 g load on the outward path as an index.
Horn layer cells were collected from the same subject by tape stripping, and immunostaining of desmoglein 1 of the stratum corneum cells was performed in the same manner as in Test Example 2. From the obtained immunostained image, the ratio of the number of pixels showing desmoglein 1 to the total number of pixels was calculated in the same manner as in Test Example 4.
Correlation analysis between the frequency change (Δf) value and the ratio was performed using analysis software (JMP ver. 10.0 (manufactured by SAS)).
結果を図10に示す。コルネオデスモゾームの分解が進み、バスケットウィーブ角層形成度合いが高いほど、周波数変化(Δf)値の絶対値が大きく、角層柔軟性が高いことが示された。この結果からも、バスケットウィーブ角層の形成により、角層柔軟性が向上することが明らかとなった。 The results are shown in FIG. It was shown that the higher the degree of basket weave stratum corneum formation, the larger the absolute value of the frequency change (Δf) value, and the higher the stratum corneum flexibility, as the decomposition of the corneodesmosome progressed. From this result, it was clarified that the formation of the basket weave horny layer improves the horny layer flexibility.
<試験例7>バスケットウィーブ角層の成分貯留性・浸透性の検討
試験例3と同様に、三次元皮膚培養モデルを用いて、バスケットウィーブ角層及びコンパクト角層の試料を作製した。
作成後の試料に対して、色素(0.05%トルイジンブルー溶液)を100μL添加して37℃にて培養した。3時間後に組織を回収し、OCTコンパウンドにて凍結包埋し、常法通りに組織切片を作製した。光学顕微鏡観察により、表皮における色素の局在状態を観察した。
<Test Example 7> Examination of component retention and permeability of basket weave horny layer Similar to Test Example 3, samples of basket weave horny layer and compact horny layer were prepared using a three-dimensional skin culture model.
To the prepared sample, 100 μL of a dye (0.05% toluidine blue solution) was added and cultured at 37 ° C. After 3 hours, the tissue was collected, frozen and embedded in an OCT compound, and tissue sections were prepared as usual. By observing with an optical microscope, the localization state of the pigment in the epidermis was observed.
結果を図11に示す。バスケットウィーブ角層を形成した三次元培養皮膚モデルは、コンパクト角層の三次元培養皮膚モデルと比較して、角層における色素の貯留が大きいことがわかる。また、コンパクト角層の三次元培養皮膚モデルでは表皮層への色素の浸透はみられないが、バスケットウィーブ角層を形成した三次元培養皮膚モデルでは表皮層へ色素が浸透している様子が確認された。この結果から、バスケットウィーブ角層の形成により、肌における有効成分の貯留性・浸透性が向上する可能性が示された。 The results are shown in FIG. It can be seen that the three-dimensional cultured skin model in which the basket weave stratum corneum is formed has a larger pigment retention in the stratum corneum than the three-dimensional cultured skin model of the compact stratum corneum. In addition, the three-dimensional cultured skin model of the compact stratum corneum did not show pigment penetration into the epidermis layer, but the three-dimensional cultured skin model that formed the basket weave stratum corneum confirmed that the pigment penetrated into the epidermis layer. Was done. From this result, it was shown that the formation of the basket weave stratum corneum may improve the retention and permeability of the active ingredient in the skin.
本発明により、それ自体が肌状態改善作用を発揮する化粧料基剤が提供される。また、肌状態改善用化粧料基剤を、非侵襲的で簡便に探索できるスクリーニング方法が提供される。化粧料基剤自体に付加価値がつき、また化粧料の処方設計の幅が広がるため、産業上非常に有用である。 INDUSTRIAL APPLICABILITY The present invention provides a cosmetic base that itself exerts a skin condition improving effect. In addition, a screening method that can easily search for a cosmetic base for improving skin condition is provided. It is very useful in industry because it adds value to the cosmetic base itself and expands the range of prescription designs for cosmetics.
Claims (2)
前記バスケットウィーブ角層形成を、前記培養皮膚の断面の観察により評価する工程を含む、方法。 A screening method for a cosmetic base for improving skin condition, using basket weave stratum corneum formation in cultured skin as an index.
A method comprising the step of evaluating the basket weave stratum corneum formation by observing a cross section of the cultured skin.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015158793 | 2015-08-11 | ||
JP2015158793 | 2015-08-11 | ||
JP2015251623 | 2015-12-24 | ||
JP2015251623 | 2015-12-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017119665A JP2017119665A (en) | 2017-07-06 |
JP2017119665A5 JP2017119665A5 (en) | 2019-04-25 |
JP6863548B2 true JP6863548B2 (en) | 2021-04-21 |
Family
ID=59271537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016094588A Active JP6863548B2 (en) | 2015-08-11 | 2016-05-10 | Cosmetic base for improving skin condition and its screening method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6863548B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202112996PA (en) | 2019-05-23 | 2021-12-30 | Pola Chem Ind Inc | Method for screening component that affects fluctuation of adhesion proteins in stratum corneum cells |
JP7360283B2 (en) * | 2019-09-11 | 2023-10-12 | ポーラ化成工業株式会社 | A method for comparing and observing the location of a specific protein with the geometric characteristics of the stratum corneum itself and/or the location of a specific tissue within the stratum corneum |
JP7485462B2 (en) * | 2019-11-29 | 2024-05-16 | ポーラ化成工業株式会社 | Desmograin amount estimation device and estimation program, and skin blemish concentration estimation device and estimation program |
JP7419120B2 (en) * | 2020-03-17 | 2024-01-22 | 株式会社ナリス化粧品 | Corner layer peel improving agent and its screening method |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01301617A (en) * | 1988-05-30 | 1989-12-05 | Nonogawa Shoji:Kk | Gel base for percutaneous absorption, production thereof and o/w emulsion base obtained therefrom |
JP3453871B2 (en) * | 1994-08-31 | 2003-10-06 | 株式会社資生堂 | Evaluation method of desmosome function |
JP3128112B2 (en) * | 1995-03-23 | 2001-01-29 | 日清製油株式会社 | Moisture retaining composition and base containing the same |
JP4805794B2 (en) * | 2005-12-28 | 2011-11-02 | 株式会社コーセー | Method for detecting stratum corneum protein, method for evaluating epidermal turnover and method for evaluating skin condition using the same |
ES2689170T3 (en) * | 2009-08-31 | 2018-11-08 | Avon Products, Inc. | Cosmetic uses of modified stressed yeast extracts and related compositions |
JP5970184B2 (en) * | 2011-12-26 | 2016-08-17 | 株式会社 資生堂 | Evaluation method of cosmetics |
-
2016
- 2016-05-10 JP JP2016094588A patent/JP6863548B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017119665A (en) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4834775B2 (en) | Sunscreen composition | |
JP5327911B2 (en) | Oxidative hair dye | |
JP6863548B2 (en) | Cosmetic base for improving skin condition and its screening method | |
WO2010134562A1 (en) | Cosmetic preparation | |
TWI771348B (en) | Oil-in-water composition | |
KR101773536B1 (en) | Sunscreen cosmetic composition containing ultraviolet absorber | |
ES2691276T3 (en) | Polymerosome and procedure for its production | |
JP3471601B2 (en) | External preparation for skin | |
JP5414064B2 (en) | Cosmetics | |
JP5413977B2 (en) | Cosmetics | |
JPWO2018088570A1 (en) | Skin preparation for external use | |
TW201801710A (en) | [alpha]-gel forming composition and [alpha]-gel composition | |
JPWO2020054827A1 (en) | Water-in-oil type skin external composition | |
JP6699844B2 (en) | Emulsified composition | |
TW202015655A (en) | Composition | |
JP6835439B2 (en) | Sunscreen cosmetics | |
TWI825218B (en) | Powder dispersion composition and manufacturing method thereof | |
JP7402599B2 (en) | Water-in-oil emulsion composition | |
JP7436382B2 (en) | Cosmetic manufacturing method | |
JP6387261B2 (en) | Melanin production inhibitor | |
JP2017007980A (en) | Liquid crystal cosmetic | |
JPWO2020110606A1 (en) | Detergent composition | |
JP7003360B2 (en) | Solid powder cosmetics | |
JP2021161083A (en) | Method for promoting horny layer maturation | |
JP2021187804A (en) | Oil-in-water emulsion composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190318 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190318 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200305 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200901 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201009 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210302 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210317 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6863548 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |